Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

AbstractAboutThe 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  HIV Infection

  Free Subscription


Articles published in J Acquir Immune Defic Syndr

Retrieve available abstracts of 414 articles:
HTML format



Single Articles


    November 2025
  1. HALLMARK CJ, France AM, Linley L, Lyss SB, et al
    Characteristics of HIV Time-Space Alerts in the United States, 2018-2021.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003795.
    PubMed     Abstract available


  2. DRUMRIGHT LN, Delaney JA, Crawford T, Whitney BM, et al
    Longitudinal associations between internalized HIV stigma and lower HIV antiretroviral therapy adherence among people with HIV.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003793.
    PubMed     Abstract available


  3. LAXMESHWAR C, Hegde A, Dange A, Mariyappan K, et al
    Virtual model for HIV self-testing demand generation and kit distribution: Results from the STAR III study in India.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003792.
    PubMed     Abstract available


  4. NGUYEN T, Chae JW, Ziemba L, Coletti A, et al
    Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTED.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003796.
    PubMed     Abstract available


  5. WAMAKIMA B, Diouf K, Modest A, Macharia A, et al
    Pre-eclampsia Rates in Women with and without HIV in Modern ART Era in Botswana.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003791.
    PubMed    


  6. UMUTONI V, Eavou R, Almirol E, Neumann MS, et al
    A Community Located Insurance Navigation Intervention to link Sexual and Gender Minorities in Status Neutral Care: Results from the NICE Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2025 Nov 3. doi: 10.1097/QAI.0000000000003788.
    PubMed     Abstract available


    October 2025
  7. KHANNA A, Lee F, Schrode K, Sheeler D, et al
    Long-acting injectable PrEP can substantially reduce HIV incidence in Los Angeles County: A simulation study.
    J Acquir Immune Defic Syndr. 2025 Oct 30. doi: 10.1097/QAI.0000000000003790.
    PubMed     Abstract available


  8. IQBAL K, Crim SM, Tie Y, Cholli P, et al
    Availability of substance use services at U.S. HIV care facilities by urbanicity.
    J Acquir Immune Defic Syndr. 2025 Oct 28. doi: 10.1097/QAI.0000000000003789.
    PubMed     Abstract available


  9. KEDDEM S, Sorrentino A, Agha AZ, Colt SF, et al
    Exploring PrEP Uptake in Young Women Veterans: Insights from a Detailed Chart Review within the Veterans Health Administration.
    J Acquir Immune Defic Syndr. 2025 Oct 24. doi: 10.1097/QAI.0000000000003782.
    PubMed     Abstract available


  10. MAGONGO EN, Hast M, Nabitaka V, Nakanwagi M, et al
    Low Levels of Clinically Significant Drug Resistance Mutations to Dolutegravir amongst Children Living with HIV Failing on First-line Antiretroviral Therapy in Uganda.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003784.
    PubMed     Abstract available


  11. ADESSE D, Torices S, Alcaide ML, Beurel E, et al
    Plasma biomarkers of neurogenesis are increased among people with HIV after COVID.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003785.
    PubMed     Abstract available


  12. LARSON ME, Pan Y, Lakhani F, Chavez J, et al
    The association between cannabis use and electrocardiographic abnormalities in people living with HIV.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003786.
    PubMed     Abstract available


  13. ORKIN C, Kuritzkes DR, Katlama C, Su FH, et al
    Doravirine Resistance Patterns Identified through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.
    J Acquir Immune Defic Syndr. 2025 Oct 23. doi: 10.1097/QAI.0000000000003787.
    PubMed     Abstract available


  14. D K, C R, B C, H RG, et al
    Factors Associated with Preference for Long-Acting Injectable versus Daily Oral Antiretroviral Therapy among People with HIV: Findings from the SELIGO Study.
    J Acquir Immune Defic Syndr. 2025 Oct 22. doi: 10.1097/QAI.0000000000003781.
    PubMed     Abstract available


  15. ISLEK D, Sanchez T, Baral S, Caldwell JA, et al
    Characteristics associated with the HIV Pre-exposure prophylaxis care continuum among transfeminine persons in the United States.
    J Acquir Immune Defic Syndr. 2025 Oct 22. doi: 10.1097/QAI.0000000000003783.
    PubMed     Abstract available


  16. MCHENRY MS, Huo Y, Williams PL, Patel K, et al
    Plasma inflammatory biomarkers lack strong association with cognitive outcomes among young adults with perinatal HIV exposure and/or acquisition.
    J Acquir Immune Defic Syndr. 2025 Oct 14. doi: 10.1097/QAI.0000000000003771.
    PubMed     Abstract available


  17. HSUE PY, Behrens GMN, Xu ZJ, Zhao Y, et al
    Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Model After Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.
    J Acquir Immune Defic Syndr. 2025 Oct 13. doi: 10.1097/QAI.0000000000003778.
    PubMed     Abstract available


  18. ROSENBERG NE, Young AM, Zou Y, Justman J, et al
    An HIV-1 risk assessment tool for men aged 15-59 years in 13 African countries: A pooled analysis of nationally representative surveys.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003773.
    PubMed     Abstract available


  19. DAHAL S, Logan J, Kanagasabai U, Annor F, et al
    Differential associations of violence and mental health outcomes by HIV status among adolescent girls and young women aged 15-24 years in 5 countries in Sub-Saharan Africa, 2018/2019.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003769.
    PubMed     Abstract available


  20. CEBULA BR, Frndak S, Hamby T, Esber A, et al
    COVID-19 Knowledge, Attitudes, and Practices among People with and Without HIV in Four Countries in Sub-Saharan Africa.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003770.
    PubMed     Abstract available


  21. CHANDRAN A, Olson S, Edmonds A, Moran CA, et al
    Trajectories of BMI Before, During and Following the COVID-19 Pandemic among Participants in the MACS/WIHS Combined Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003779.
    PubMed     Abstract available


  22. WEINSTEIN ER, Kirakosian N, Chen YO, Bharat B, et al
    Life Instability and its Effects on Psychosocial Syndemic Problems and HIV-Care Outcomes in People Living with HIV in Care in South Florida.
    J Acquir Immune Defic Syndr. 2025 Oct 9. doi: 10.1097/QAI.0000000000003777.
    PubMed     Abstract available


  23. ALFORD K, Fitzpatrick C, Rhodes S, O'Brien C, et al
    Addressing cognitive symptoms in people with HIV: Outcomes from a holistic screening and management pathway.
    J Acquir Immune Defic Syndr. 2025 Oct 8. doi: 10.1097/QAI.0000000000003775.
    PubMed     Abstract available


  24. FIEGGEN J, Meintjes G, Boulle A, Euvrard J, et al
    Characteristics of Individuals with Advanced HIV Disease and Risk Factors for Mortality in a Contemporary Cohort in South Africa.
    J Acquir Immune Defic Syndr. 2025 Oct 6. doi: 10.1097/QAI.0000000000003767.
    PubMed     Abstract available


  25. BHUSHAN NL, Boudewyns V, Getachew-Smith H, Stryker JE, et al
    Pre-Exposure Prophylaxis (PrEP) Guideline Awareness and Prescribing Behaviors Among Healthcare Providers in the United States: DocStyles Survey, 2022-2024.
    J Acquir Immune Defic Syndr. 2025 Oct 6. doi: 10.1097/QAI.0000000000003774.
    PubMed     Abstract available


  26. STEVENSON M, Cooney E, Borquez A, Radix AE, et al
    Undiagnosed HIV among transgender women in the United States: Implications for testing programs.
    J Acquir Immune Defic Syndr. 2025 Oct 6. doi: 10.1097/QAI.0000000000003776.
    PubMed     Abstract available


    September 2025
  27. VYAS KJ, Moreland S, Esser S, Jessen H, et al
    Trends in Online and In-Person Sex-Seeking Venues among Men who have Sex with Men in Berlin, Germany.
    J Acquir Immune Defic Syndr. 2025 Sep 25. doi: 10.1097/QAI.0000000000003766.
    PubMed     Abstract available


  28. HENRY RT, Khol V, Duy CD, Marbaniang I, et al
    Low Cholesterol associated with TB in people living with HIV in an Asia-Pacific cohort.
    J Acquir Immune Defic Syndr. 2025 Sep 18. doi: 10.1097/QAI.0000000000003761.
    PubMed     Abstract available


  29. MELNYCHUK S, Green K, Ejeckam C, Adesina A, et al
    HIV drug resistance among key populations in Nigeria: Insights from the 2020 integrated biological and behavioural surveillance survey.
    J Acquir Immune Defic Syndr. 2025 Sep 11. doi: 10.1097/QAI.0000000000003763.
    PubMed     Abstract available


  30. STRACKER N, Rives S, Schumacher CM, Hamill MM, et al
    Addressing Health Disparities Associated with the HIV PrEP Initiation Cascade, Baltimore City Health Department Sexual Health Clinics, 2016-2023.
    J Acquir Immune Defic Syndr. 2025 Sep 11. doi: 10.1097/QAI.0000000000003764.
    PubMed     Abstract available


  31. CARROZZO G, Pozza G, Poloni A, Caronni S, et al
    Evolution of causes of death in People with HIV between 2000 and 2023: a single center retrospective Study.
    J Acquir Immune Defic Syndr. 2025 Sep 10. doi: 10.1097/QAI.0000000000003762.
    PubMed    


  32. KELLY NK, Ranapurwala SI, Pence BW, Hightow-Weidman LB, et al
    The effect of state-level policy climate on HIV pre-exposure prophylaxis use and the role of internalized stigma.
    J Acquir Immune Defic Syndr. 2025 Sep 4. doi: 10.1097/QAI.0000000000003760.
    PubMed     Abstract available


  33. MORGAN E, McDade TW, Manning W, Kamp Dush CM, et al
    Assessing Inflammatory Biomarkers at the Intersection of Marijuana and PrEP Use: Preliminary findings from the NCHAT-BIO study.
    J Acquir Immune Defic Syndr. 2025 Sep 4. doi: 10.1097/QAI.0000000000003759.
    PubMed     Abstract available


  34. KNETTEL BA, Madundo K, Amiri I, Msoka EF, et al
    Results of a Pilot Randomized Controlled Trial of IDEAS for Hope, a Brief Telehealth Intervention for Suicide Prevention and HIV Care Engagement in Tanzania.
    J Acquir Immune Defic Syndr. 2025 Sep 4. doi: 10.1097/QAI.0000000000003758.
    PubMed     Abstract available


  35. SPENCE AB, Visconti A, Goparaju L, Wingood G, et al
    Anticipated protection overcomes vaccine hesitancy and mistrust among women enrolled in the DC MACS/WIHS Combined Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Sep 3. doi: 10.1097/QAI.0000000000003757.
    PubMed     Abstract available


    August 2025
  36. FRIEDLAND BA, Browne EN, Roberts ST, Ngure K, et al
    Higher acceptability of the monthly dapivirine ring versus daily oral pre-exposure prophylaxis among adolescent girls and young women in sub-Saharan Africa in the REACH trial.
    J Acquir Immune Defic Syndr. 2025 Aug 28. doi: 10.1097/QAI.0000000000003756.
    PubMed     Abstract available


  37. WANG H, Kolstee J, Gaetani M, Aphami L, et al
    Interest in and preference for long-acting injectable PrEP among men who have sex with men, trans* individuals, and cis-gender heterosexual women: a global systematic review and meta-analysis.
    J Acquir Immune Defic Syndr. 2025 Aug 27. doi: 10.1097/QAI.0000000000003754.
    PubMed     Abstract available


  38. D'ANTONI ML, Boopathy AV, Andreatta K, Chang S, et al
    HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLIANCE Study.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003749.
    PubMed    


  39. QIAN Y, Comulada WS, Hidalgo MA, Lee SJ, et al
    Depression improves the predictive accuracy of the VACS Index 2.0 for all-cause mortality among sexual minority men living with HIV in the Multicenter AIDS Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003752.
    PubMed     Abstract available


  40. MADLALA HP, Jao J, Roussos G, Mendham AE, et al
    Gluteal adipose tissue mitochondrial respiration and insulin sensitivity in pregnant South African women living with HIV on Tenofovir-Lamivudine-Dolutegravir.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003755.
    PubMed     Abstract available


  41. BERRY DL, Orr JE, Schmickl CN, DeYoung Rpsgt P, et al
    Effects of Treating Obstructive Sleep Apnea on Common Symptoms of HIV.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003753.
    PubMed     Abstract available


  42. CHIROMBO J, Lora WS, Sakala D, Shahmanesh M, et al
    An exploratory study using respondent-driven sampling to map HIV risk across sex work locations in Blantyre, Malawi.
    J Acquir Immune Defic Syndr. 2025 Aug 26. doi: 10.1097/QAI.0000000000003746.
    PubMed     Abstract available


  43. MOYO S, Yankinda EK, Hurwitz KE, Bennett K, et al
    Predictors of Concurrent Sexual Partnerships and Association with Recent HIV Infection in a Large Population-Based Survey in Botswana.
    J Acquir Immune Defic Syndr. 2025 Aug 22. doi: 10.1097/QAI.0000000000003751.
    PubMed     Abstract available


  44. KALATA NL, Bello G, Pals S, Kabaghe AN, et al
    HIV Drug Resistance to Dolutegravir Among Adults Investigated for Anti-retroviral Treatment Failure in Malawi: A 2023 National Cross-sectional Survey.
    J Acquir Immune Defic Syndr. 2025 Aug 21. doi: 10.1097/QAI.0000000000003744.
    PubMed    


  45. JONES J, Schneider I, Valencia R, Jenness SM, et al
    Randomized controlled trial of a HIV prevention app to increase pre-exposure prophylaxis uptake among gay and bisexual men who have sex with men in the United States: The HealthMindr PrEP study.
    J Acquir Immune Defic Syndr. 2025 Aug 19. doi: 10.1097/QAI.0000000000003747.
    PubMed     Abstract available


  46. YANG G, Dale I, Zarwell M, Elkins JS, et al
    Harnessing Egocentric Networks to Inform an Enhanced Social Network Strategy in a Southern US "Ending the HIV Epidemic" Region.
    J Acquir Immune Defic Syndr. 2025 Aug 19. doi: 10.1097/QAI.0000000000003750.
    PubMed     Abstract available


  47. CHANG GC, Bingham T, Patel HK, Mungai E, et al
    Undetectable HIV-1 viral load among virally suppressed people living with HIV: implications for Undetectable equals Untransmittable (U=U) in resource-limited settings using dried spot testing.
    J Acquir Immune Defic Syndr. 2025 Aug 15. doi: 10.1097/QAI.0000000000003745.
    PubMed     Abstract available


  48. HAY WONG JM, Balleny R, Lee T, Bitnun A, et al
    Perinatal and early infant outcomes after bictegravir exposure in pregnancy: a Canadian surveillance study.
    J Acquir Immune Defic Syndr. 2025 Aug 14. doi: 10.1097/QAI.0000000000003708.
    PubMed     Abstract available


  49. COMINS CA, Genberg B, Mcingana M, Bandeen-Roche K, et al
    Longitudinal trajectories of engagement with HIV treatment support strategies among female sex workers living with HIV in South Africa.
    J Acquir Immune Defic Syndr. 2025 Aug 14. doi: 10.1097/QAI.0000000000003738.
    PubMed     Abstract available


  50. BOOPATHY AV, D'Antoni ML, Andreatta K, Chang S, et al
    Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Participants with Preexisting K65R/N in HIV-1 in Phase 2/3/3b Clinical Trials.
    J Acquir Immune Defic Syndr. 2025 Aug 8. doi: 10.1097/QAI.0000000000003742.
    PubMed     Abstract available


  51. DZOMBA A, Shumba K, Nattey C, Lauren E, et al
    HIV patient treatment adherence trajectories in first 24-months post-ART initiation among adults: an electronic health records cohort from South Africa.
    J Acquir Immune Defic Syndr. 2025 Aug 8. doi: 10.1097/QAI.0000000000003736.
    PubMed     Abstract available


  52. PALOMARES M, Shade SB, Pollack L, Zand P, et al
    Enthusiasm for Participation in a Novel, At-Home Delivery Model for Injectable HIV Treatment among People with HIV.
    J Acquir Immune Defic Syndr. 2025 Aug 8. doi: 10.1097/QAI.0000000000003743.
    PubMed    


  53. NJUGUNA I, Maleche-Obimbo E, Mugo C, Begnel ER, et al
    Herpesvirus viremia, ART response, and growth recovery in Kenyan children starting antiretroviral therapy in hospital.
    J Acquir Immune Defic Syndr. 2025 Aug 7. doi: 10.1097/QAI.0000000000003741.
    PubMed     Abstract available


  54. HIGGINS N, Patel N, Solso S, Dullano C, et al
    Relationship between Opioid Use, Depression and Quality of Life among Persons with HIV at End of Life.
    J Acquir Immune Defic Syndr. 2025 Aug 4. doi: 10.1097/QAI.0000000000003737.
    PubMed    


  55. NUTT CT, Muyindike WR, Nanfuka V, Komukama N, et al
    Factors Associated with Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda.
    J Acquir Immune Defic Syndr. 2025 Aug 4. doi: 10.1097/QAI.0000000000003735.
    PubMed     Abstract available


  56. ROSEN JG, Esso Y, Keugoung B, Lwamba C, et al
    Sexual partnership heterogeneity and HIV seropositivity among adolescent girls and young women in Cameroon and Cote d'Ivoire: a partner-level latent class analysis.
    J Acquir Immune Defic Syndr. 2025 Aug 1. doi: 10.1097/QAI.0000000000003740.
    PubMed    


  57. MCGILL LS, Clay OJ, Edwards KA, Jones KF, et al
    Trajectories of Pain Impact and Pain Self-Efficacy in People with HIV and Chronic Pain: Extending Findings from the Skills TO Manage Pain (STOMP) Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2025 Aug 1. doi: 10.1097/QAI.0000000000003739.
    PubMed     Abstract available


    July 2025
  58. MOODY K, Verburgh ML, Stutterheim SE, F Schim Van Der Loeff M, et al
    Stigma-related disclosure concerns and negative self-image have not improved over a decade in older people with HIV.
    J Acquir Immune Defic Syndr. 2025 Jul 28. doi: 10.1097/QAI.0000000000003732.
    PubMed     Abstract available


  59. WONG IKJ, Dyer CEF, Grulich AE, Jin F, et al
    Anal Cancer Screening in People Living with HIV: A Pilot Study of Primary HPV Screening with Triage Use of p16/Ki67 Dual Stain.
    J Acquir Immune Defic Syndr. 2025 Jul 28. doi: 10.1097/QAI.0000000000003731.
    PubMed     Abstract available


  60. BYAKWAGA H, Semeere A, Laker-Oketta M, Busakhala N, et al
    Survival Following Diagnosis of HIV-Associated Kaposi Sarcoma Among Adults in East Africa in the "Treat-All" Era.
    J Acquir Immune Defic Syndr. 2025 Jul 28. doi: 10.1097/QAI.0000000000003733.
    PubMed     Abstract available


  61. MOTLHAOLENG K, Vilakazi-Nhlapo K, Shearer K, Golub JE, et al
    Characterization of the targeted universal tuberculosis testing care cascade among people with HIV in PEPFAR-supported districts in South Africa.
    J Acquir Immune Defic Syndr. 2025 Jul 24. doi: 10.1097/QAI.0000000000003729.
    PubMed    


  62. SALAZAR J, Coffey S, Bloome J, Hickey MD, et al
    Outcomes of Rapid Restart among People with Previously Diagnosed HIV at a Safety-Net HIV Clinic in San Francisco.
    J Acquir Immune Defic Syndr. 2025 Jul 24. doi: 10.1097/QAI.0000000000003727.
    PubMed     Abstract available


  63. CONLEY H, Oh SY, Garrett N, Kublin J, et al
    IgG and Fc receptor genetic variation associates with functional antibody responses in a DNA and protein candidate HIV vaccine trial.
    J Acquir Immune Defic Syndr. 2025 Jul 24. doi: 10.1097/QAI.0000000000003734.
    PubMed     Abstract available


  64. KUNKEL A, Alioum A, Lot F, Cazein F, et al
    HIV incidence, migration and diagnosis dynamics, France, 2012-2023: a surveillance and modeling data analysis.
    J Acquir Immune Defic Syndr. 2025 Jul 24. doi: 10.1097/QAI.0000000000003730.
    PubMed     Abstract available


  65. GANGULY S, Christman O, Yang Q, Mehta C, et al
    Influence of Housing Status on Health Outcomes for Reproductive-Age Women With and Without HIV in the Southern United States.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003722.
    PubMed     Abstract available


  66. CABELLO-UBEDA A, Lopez Bernardo de Quiros JC, Mena A, Torralba M, et al
    Dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naive adults with HIV with and without genotypic resistance testing results. 96-Week effectiveness and tolerability of REDOLA study.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003721.
    PubMed    


  67. ANDERS J, Freeman A, Hou B, Sone P, et al
    HIV testing among transgender and other gender diverse persons in the United States: A scoping review.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003728.
    PubMed     Abstract available


  68. JADALLAH HG, O'Connor LF, Byrne M, Baskaran A, et al
    Understanding the Impact of Antiretroviral Therapy and Other Factors on HPV Clearance in Cisgender Women with HIV/HPV Co-infections in the DC Cohort.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003726.
    PubMed     Abstract available


  69. RODRIGUEZ AE, Botero V, Geffrard A, Saltzman RG, et al
    Entering HIV Medical Care with AIDS in the Era of Immediate Access to Antiretroviral Treatment.
    J Acquir Immune Defic Syndr. 2025 Jul 17. doi: 10.1097/QAI.0000000000003725.
    PubMed     Abstract available


  70. GOVENDER NP, Greene GS, Hullsiek KH, DeSanto D, et al
    Effectiveness of a national reflex laboratory cryptococcal antigen screening programme for people with advanced HIV disease in South Africa: a nationwide-sampled cohort study (CAST-NET).
    J Acquir Immune Defic Syndr. 2025 Jul 15. doi: 10.1097/QAI.0000000000003724.
    PubMed     Abstract available


  71. MARANO-LEE M, Williams W, Xu S, Uhl G, et al
    Adults Aged >/=50 Years Reached by the CDC's HIV Programs Including HIV Testing, PrEP Referrals, and Linkage to Care in the U.S., Puerto Rico, and the U.S. Virgin Islands, 2019-2022.
    J Acquir Immune Defic Syndr. 2025 Jul 14. doi: 10.1097/QAI.0000000000003723.
    PubMed     Abstract available


    June 2025
  72. VIOLETTE LR, Delacruz J, Niemann LA, Cannon C, et al
    Preferences for HIV PrEP Products and Delivery Models Among Cisgender Men, Transgender Persons, and Non-binary Individuals Who Have Sex with Men in Seattle, Washington: A Discrete Choice Experiment.
    J Acquir Immune Defic Syndr. 2025 Jun 24. doi: 10.1097/QAI.0000000000003718.
    PubMed     Abstract available


  73. YAO TJ, Zhang J, Malee K, Smith R, et al
    Prenatal Antiretroviral Exposure and Concomitant Neurodevelopmental Problems among 5-year-old Children who are HIV-Exposed and Uninfected.
    J Acquir Immune Defic Syndr. 2025 Jun 24. doi: 10.1097/QAI.0000000000003720.
    PubMed     Abstract available


  74. RANZENIGO M, Diotallevi S, Lolatto R, Castagna A, et al
    Prevalence and incidence of metabolic syndrome in people with HIV receiving cabotegravir and rilpivirine.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003719.
    PubMed    


  75. HILFIKER A, Schoepf IC, Avery EF, Ledergerber B, et al
    Mycobacterium tuberculosis Infection and Acute or Subclinical Coronary Artery Disease: the Swiss HIV Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003714.
    PubMed     Abstract available


  76. GIBBS A, Chirwa E, Harling G, Chimbindi N, et al
    Young men's experiences of violence and poverty and the relationship to sexually transmissible HIV: a cross sectional study from rural South Africa.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003709.
    PubMed     Abstract available


  77. YANG X, Zhang J, Ma Y, Chen S, et al
    Clinical documentation of social determinants of health and its relationship with COVID-19 outcomes among people with and without HIV.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003717.
    PubMed     Abstract available


  78. MA J, Nance RM, Ruderman SA, Drumright LN, et al
    Impact of Depressive Symptom Severity on Stroke Risk in a US Cohort of People with HIV.
    J Acquir Immune Defic Syndr. 2025 Jun 20. doi: 10.1097/QAI.0000000000003710.
    PubMed     Abstract available


  79. XU L, Youngson E, Lin M, Dwivedi R, et al
    Hospital-based healthcare service utilization in persons with HIV with or without mental health and substance use comorbidities.
    J Acquir Immune Defic Syndr. 2025 Jun 19. doi: 10.1097/QAI.0000000000003716.
    PubMed     Abstract available


  80. ANDERSON PL, Coppinger C, Cottrell ML, Marzinke MA, et al
    Recommendations for interpreting intraerythrocytic tenofovir-diphosphate and emtricitabine-triphosphate for PrEP adherence assessment.
    J Acquir Immune Defic Syndr. 2025 Jun 19. doi: 10.1097/QAI.0000000000003715.
    PubMed     Abstract available


  81. KAY ES, Bassler JR, Goebel MC, Browne L, et al
    Retention in HIV Care Still Matters: A Longitudinal Multisite Analysis.
    J Acquir Immune Defic Syndr. 2025 Jun 18. doi: 10.1097/QAI.0000000000003711.
    PubMed     Abstract available


  82. EDWARDS KA, Long D, Jones KF, Durr AL, et al
    The Skills TO Manage Pain (STOMP) Randomized Trial: Results of antiretroviral therapy adherence, HIV primary care retention, and virologic suppression outcomes.
    J Acquir Immune Defic Syndr. 2025 Jun 18. doi: 10.1097/QAI.0000000000003706.
    PubMed     Abstract available


  83. ABELMAN RA, Fitzpatrick J, Zawedde J, Beck-Engeser G, et al
    Sex and HIV Modify Immune Activation Biomarkers in Ugandans Post-Tuberculosis.
    J Acquir Immune Defic Syndr. 2025 Jun 18. doi: 10.1097/QAI.0000000000003713.
    PubMed     Abstract available


  84. AUDET CM, Seabi T, Mabuza W, Mnisi P, et al
    Can traditional health practitioners deliver HIV counseling and testing services? A pilot study in rural South Africa.
    J Acquir Immune Defic Syndr. 2025 Jun 18. doi: 10.1097/QAI.0000000000003712.
    PubMed     Abstract available


  85. KAMPHUIS AEM, Waalewijn H, Wasmann RE, Bamford A, et al
    Pharmacokinetic data of atazanavir/ritonavir in second-line treatment of children living with HIV.
    J Acquir Immune Defic Syndr. 2025 Jun 16. doi: 10.1097/QAI.0000000000003704.
    PubMed     Abstract available


  86. BOLLINGER J, Geller G, Mehta SR, Little SJ, et al
    Clinician perspectives on disclosing public health uses of HIV antiretroviral resistance testing results.
    J Acquir Immune Defic Syndr. 2025 Jun 12. doi: 10.1097/QAI.0000000000003707.
    PubMed    


  87. LOGIE CH, Sokolovic N, Casale A, Kennedy VL, et al
    Pathways from childhood abuse history to adulthood mental health among Women Living with HIV in Canada: longitudinal cohort findings.
    J Acquir Immune Defic Syndr. 2025 Jun 10. doi: 10.1097/QAI.0000000000003701.
    PubMed     Abstract available


  88. LABARILE M, Thorball CW, Hodel F, Fellay J, et al
    Polygenic Risk Scores for Type 2 Diabetes in the Swiss HIV Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jun 6. doi: 10.1097/QAI.0000000000003702.
    PubMed     Abstract available


  89. NDONGO FA, Kana R, Sambo DA, Ketchaji A, et al
    Effectiveness of community-based peer facilitated psychological and social support interventions on improving mental health in Cameroonian adolescents with perinatal HIV: the IAS-CIPHER-2021/1214-ATE SMAVI controlled randomized trial (November 2021-Ma
    J Acquir Immune Defic Syndr. 2025 Jun 6. doi: 10.1097/QAI.0000000000003705.
    PubMed     Abstract available


  90. SHIVAKOTI R, Giganti MJ, Lederman MM, Ketchum R, et al
    Inflammation, antiretroviral therapy continuation, and HIV disease progression in postpartum women with HIV.
    J Acquir Immune Defic Syndr. 2025 Jun 6. doi: 10.1097/QAI.0000000000003703.
    PubMed     Abstract available


  91. EMU B, Kumar PN, Mills A, Berhe M, et al
    Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.
    J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003699.
    PubMed     Abstract available


  92. COOMES DM, Meisner J, Roberts DA, Rodriguez P, et al
    Maternal HIV retesting during pregnancy and postpartum among high-risk populations in Kenya, South Africa, and Ukraine: Cost-effectiveness of preventing vertical transmission.
    J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003700.
    PubMed     Abstract available


  93. CRESSEY TR, Salvadori N, Rabie H, du Toit S, et al
    Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study.
    J Acquir Immune Defic Syndr. 2025;99:195-201.
    PubMed     Abstract available


    May 2025
  94. ZHANG Y, Chow EP, Phillips TR, Fairley CK, et al
    Preferences of men who have sex with men towards the distribution of HIV self-test kits through social networks: A discrete choice experiment.
    J Acquir Immune Defic Syndr. 2025 May 30. doi: 10.1097/QAI.0000000000003696.
    PubMed     Abstract available


  95. ONWUBIKO UN, Benkeser D, Holland DP, Baral SD, et al
    Impact of Depression at HIV PrEP Initiation on Sustained PrEP Care Engagement Among US Gay and Bisexual Men.
    J Acquir Immune Defic Syndr. 2025 May 15. doi: 10.1097/QAI.0000000000003698.
    PubMed     Abstract available


  96. HUANG YA, Patel RR, Mann LM, Zhu W, et al
    Out-of-pocket costs for PrEP ancillary services among U.S. commercially insured persons, 2017-2022.
    J Acquir Immune Defic Syndr. 2025 May 14. doi: 10.1097/QAI.0000000000003695.
    PubMed     Abstract available


  97. PATTEN G, Haas AD, Davies MA, Maartens G, et al
    Association between changes in script renewal periods and HIV viral non-suppression: a cohort study of a South African private-sector HIV program.
    J Acquir Immune Defic Syndr. 2025 May 14. doi: 10.1097/QAI.0000000000003697.
    PubMed     Abstract available


  98. SUDDERUDDIN H, Dang Z, Watson B, Atkinson K, et al
    Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples.
    J Acquir Immune Defic Syndr. 2025 May 13. doi: 10.1097/QAI.0000000000003694.
    PubMed     Abstract available


  99. RYAN AS, Briggs BC, Lozano AJ, Iranmanesh A, et al
    Randomized Clinical Trial of High Intensity Exercise in People with HIV: Effects on Muscle Composition and Inflammation.
    J Acquir Immune Defic Syndr. 2025 May 8. doi: 10.1097/QAI.0000000000003692.
    PubMed     Abstract available


  100. DESISTO CL, Dada D, Pathela P, Winer RL, et al
    Vaccine effectiveness against anal HPV infection among men with HIV who have sex with men attending sexual health clinics in three United States cities, 2018-2023.
    J Acquir Immune Defic Syndr. 2025 May 8. doi: 10.1097/QAI.0000000000003691.
    PubMed     Abstract available


  101. GUIGAYOMA J, Biello K, Becker SJ, Ocean E, et al
    High HIV Testing Among Black/Latino Men Who Have Sex with Men Assigned to HIV Self-Testing in a National Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2025 May 8. doi: 10.1097/QAI.0000000000003693.
    PubMed     Abstract available


  102. O'SHEA J, Yuan X, Lu JF, Buchacz K, et al
    Barriers to Rapid Enrollment and ART Initiation Among U.S. HIV Care Facilities.
    J Acquir Immune Defic Syndr. 2025 May 8. doi: 10.1097/QAI.0000000000003690.
    PubMed     Abstract available


  103. ATUJUNA M, Nyamaizi AM, Duby Z, Minnis A, et al
    Men's Voices on Long-Acting Pre-Exposure Prophylaxis Delivery Modalities: Acceptability and Preferences Among Cisgender Men and Men Who Have Sex With Men in South Africa.
    J Acquir Immune Defic Syndr. 2025;99:55-63.
    PubMed     Abstract available


  104. WANG H, Delnoij M, Zimmermann HML, Jonas KJ, et al
    The Disparities of PrEP Adherence Among Men Who Have Sex With Men Between the Global South and the Global North: An Updated Determinantal Global Meta-Analysis.
    J Acquir Immune Defic Syndr. 2025;99:1-8.
    PubMed     Abstract available


    April 2025
  105. LOVELACE TC, Gelhaus SL, Methe B, Mullett SJ, et al
    Identifying Metabolomic Biomarkers of Lung Function Decline in People with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 29. doi: 10.1097/QAI.0000000000003689.
    PubMed     Abstract available


  106. PHAM M, Wickremasingha P, Vargo R, Patel M, et al
    Exploratory Substudy of a Phase 2 Trial to Evaluate the Pharmacokinetic Effect of Once-Monthly Islatravir on Long-Acting Reversible Contraceptives.
    J Acquir Immune Defic Syndr. 2025 Apr 22. doi: 10.1097/QAI.0000000000003678.
    PubMed     Abstract available


  107. WILSON S, Milicic A, Javandel S, Yballa C, et al
    Amyloid-beta PET Positivity Among Cognitively Impaired People with HIV Over Age 60.
    J Acquir Immune Defic Syndr. 2025 Apr 21. doi: 10.1097/QAI.0000000000003686.
    PubMed     Abstract available


  108. HUMPHRIES DL, Audet CM, Balasubramanian BA, Benbow N, et al
    Building the Road to End the HIV Epidemic Through Coordinating and Capacity-Building Hubs to Enhance the Science of HIV Implementation REsearch (CHESHIRE): Reflections and Directions: Erratum.
    J Acquir Immune Defic Syndr. 2025 Apr 18. doi: 10.1097/QAI.0000000000003684.
    PubMed    


  109. MAROTTA PL, Humphries D, Escudero D, Katz DA, et al
    Strengthening the US Health Workforce to End the HIV Epidemic: Lessons Learned From 11 EHE Jurisdictions: Erratum.
    J Acquir Immune Defic Syndr. 2025 Apr 18. doi: 10.1097/QAI.0000000000003683.
    PubMed    


  110. NDONGO FA, Tejiokem MC, Penda CI, Ndiang ST, et al
    IMMUNOLOGICAL AND VIROLOGIC OUTCOMES WITHIN TEN YEARS OF COMBINED ANTIRETROVIRAL THERAPY INITIATED BEFORE ONE YEAR OF AGE IN CAMEROONIAN CHILDREN WITH PERINATAL HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003687.
    PubMed     Abstract available


  111. NAMPOTA-NKOMBA N, Buchwald A, Nyirenda OM, Mkandawire FA, et al
    Association between Maternal HIV and Adverse Birth Outcomes in the Era of Universal Antiretroviral Therapy in Malawi.
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003685.
    PubMed     Abstract available


  112. CRANE HM, Ruderman SA, Nance RM, Drumright LN, et al
    Approaches to optimally target frailty screening among people with HIV in clinical care: findings from the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS).
    J Acquir Immune Defic Syndr. 2025 Apr 17. doi: 10.1097/QAI.0000000000003688.
    PubMed     Abstract available


  113. JONES J, Siegler AJ, Glick JL, Lucas IL, et al
    Brief Report: Potential Gains in PrEP Coverage and Effect on Racial Disparities After Introduction of On-Demand and Long-Acting Injectable PrEP: Preferences of Men Who Have Sex With Men in the United States, 2021-2022.
    J Acquir Immune Defic Syndr. 2025;98:429-433.
    PubMed     Abstract available


  114. SIRIBELLI A, Diotallevi S, Galli L, Muccini C, et al
    Non-liver Malignancies as Main Cause of Mortality After HCV Eradication Among People Living With HIV: Erratum.
    J Acquir Immune Defic Syndr. 2025;98:e16.
    PubMed    


  115. DONOSO VA, Chandra S, Zamantakis A, Kassanits J, et al
    Two Pilots of an Implementation Science Training Program for HIV Prevention and Care Service Providers: Lessons Learned and Future Directions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  116. KHOSROPOUR CM, Means AR, Kerani RP, Murphy EM, et al
    Developing Implementation Science Capacity Within Health Departments Located in Ending the HIV Epidemic Priority Areas.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  117. GARNER BR, Bouris A, Charlebois ED, Li DH, et al
    The Strategies Timeline and Activities Reporting Tables: Improving HIV Care by Improving the Reporting of Implementation Strategies.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  118. KATOMSKI AS, Pachicano AM, Zamantakis A, Benbow ND, et al
    Policymaker Perspectives on Implementation Determinants of Rapid ART and Same-Day PrEP in Seven Priority Jurisdictions for Ending the HIV Epidemic: A Multisite Qualitative Study.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  119. MAROTTA PL, Humphries D, Escudero D, Katz DA, et al
    Strengthening the US Health Workforce to End the HIV Epidemic: Lessons Learned From 11 Ending the HIV Epidemic Jurisdictions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  120. MCCOY K, Mantell JE, Deiss R, Liu A, et al
    Pre-Exposure Prophylaxis Awareness and Demand Creation: Overlooked Populations and Opportunities to Move Forward.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  121. MANTELL JE, Bauman LJ, Bonett S, Buchbinder S, et al
    Innovation in Providing Equitable Pre-exposure Prophylaxis Services in the United States: Expanding Access in Nontraditional Settings.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  122. BROWN LL, Batchelder AW, Gondre-Lewis MC, Willie TC, et al
    Innovations to Address Unmet Behavioral Health Needs in National Ending the HIV Epidemic Priority Jurisdictions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  123. JONES JL, Schwartz S, Kassanits JE, Pyra M, et al
    Rapid ART, Rapid PrEP, and Status Neutral Implementation in Ryan White-Funded Clinics: Results From a Multisite Survey.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  124. BELTRAN RM, Katomski AS, Bonett S, Cianelli R, et al
    Lessons Learned From Engaging Healthcare Providers in Research on Implementation of HIV Preexposure Prophylaxis.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  125. GIGUERE R, Mmeje O, Patel VV, Felsen UR, et al
    Defining Study Populations in HIV Prevention Implementation Science Studies: A Case Comparison of 3 Ending the HIV Epidemic Projects.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  126. OGUNBAJO A, Martinez O, Akiyama M, Dombrowski JC, et al
    Implementation Science Approaches to Addressing the Social and Structural Determinants of Health of Criminal-Legal Involved People Living With HIV to Improve HIV Care Outcomes.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  127. NOWOTNY KM, Culbertson K, Akiyama MJ, Callen E, et al
    Integrating People With Lived Experience of Carceral System Involvement Into Research: Lessons Learned From Ending the HIV Epidemic Research Teams.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  128. RODRIGUEZ-DIAZ CE, Jaramillo J, Santiago-Rivera Y, Harkness A, et al
    Language Justice in Implementation Science: Experiences Working With Latinxs to End the HIV Epidemic.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  129. SHAH HS, Serrano PA, Rodriguez-Diaz CE, Page KR, et al
    Not a Monolith: Regional HIV Implementation Science Lessons With Latino/a/x Populations.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  130. MACAPAGAL K, Stoner MCD, Guss CE, Sukhija-Cohen AC, et al
    Lessons Learned in Engaging Adolescents and Young Adults to End the US HIV Epidemic.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  131. RODRIGUEZ-DIAZ CE, Kopeka MP, Tun W, Santiago-Rodriguez EI, et al
    Communities Started the End of the HIV Epidemic: Experiences With and Recommendations for Conducting Community-Engaged HIV Implementation Research.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  132. LANZI RG, Varley A, Ott C, Wolfner C, et al
    Implementation Science Methods, Challenges, and Associated Solutions: Transportable Lessons Learned and Best Practices From the Second National Meeting for Research and Community Collaboration Toward Ending the HIV Epidemic in the United States.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  133. SCHWARTZ S, Benbow N, Brewer RA, Beres LK, et al
    Generating Evidence for Effective HIV Implementation at Scale: The Value and Feasibility of a Network for Implementation Science in HIV.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  134. SIMON CL, Carlisle NA, Kermani M, Cole C, et al
    Community Engagement to Empowerment: Emphasizing Relationships, Process, Resources, and Context to Strengthen Community Engagement in EHE Research Partnerships.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  135. BERES LK, Harkness A, Corcoran J, Datar R, et al
    Improving Community-Engaged Implementation Science: Perspectives From "Ending the HIV Epidemic" Supplement Award Cases in the United States.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  136. DATAR R, Schwartz S, Gomez W, Katz DA, et al
    Community-Engaged Research in HIV Implementation Science: Characterizing Academic and Community Partnerships in the "Ending the HIV Epidemic" Supplement Awards.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  137. HUMPHRIES DL, Audet CM, Balasubramanian BA, Benbow N, et al
    Building the Road to End the HIV Epidemic Through Coordinating and Capacity-Building Hubs to Enhance the Science of HIV Implementation REsearch (CHESHIRE): Reflections and Directions.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  138. GORDON C, Koenig LJ, Psihopaidas D, Refsland E, et al
    Leveraging Implementation Science to End the HIV Epidemic in the United States: Progress and Opportunities for Federal Agencies.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  139. LI DH, Gaines Lanzi R, Pyra M
    Progress and Priorities to End the HIV Epidemic by 2030: Combined Lessons From 120 US Implementation Research Projects.
    J Acquir Immune Defic Syndr. 2025;98.
    PubMed     Abstract available


  140. SETIA WIRAWAN GB, Navin KS, Lila Wulandari LP, Boettiger D, et al
    Retention and viral suppression with differentiated time or space for adolescent and young adult HIV care: a systematic review and meta-analysis.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003681.
    PubMed     Abstract available


  141. MILICIC A, Wilson S, Javandel S, Allen IE, et al
    Plasma Inflammatory Biomarkers Link to Worse Cognition Among Africans with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003679.
    PubMed     Abstract available


  142. ZHU W, Huang YA, Kourtis AP, Neblett-Fanfair R, et al
    Trends in HIV preexposure prophylaxis use before and after launch of the Ending the HIV Epidemic in the U.S. initiative, 2016-2023.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003674.
    PubMed     Abstract available


  143. CHEN Y, Montano MA, Naik P, Thuo N, et al
    Incremental cost of pre- and post-exposure prophylaxis service provision via an online pharmacy in Kenya.
    J Acquir Immune Defic Syndr. 2025 Apr 8. doi: 10.1097/QAI.0000000000003680.
    PubMed     Abstract available


  144. WALL KM, Sullivan P, Shrestha RK, Dana R, et al
    Cost and cost-effectiveness of online recruitment to increase HIV self-testing among Black and Hispanic/Latino men who have sex with men in the United States, 2020-2021.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003666.
    PubMed     Abstract available


  145. MOROZOVA O, Conroy K, Riabokon S, Germanovich M, et al
    HIV Viral Rebound on Dolutegravir, Lopinavir and Efavirenz: National Program Data Analysis from Ukraine.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003676.
    PubMed     Abstract available


  146. BUNTING SR, Feinstein BA, Wilson A, Rivera J, et al
    Preferences for PrEP Implementation and Engagement in the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum among Patients Receiving Psychiatric Care in an Ending the HIV Epidemic Priority County.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003675.
    PubMed     Abstract available


  147. IZQUIERDO R, Vallejo A, Suarez-Garcia I, Martin-Hondarza A, et al
    Markers of inflammation and immune dysfunction and non-AIDS cancer risk in adults with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003667.
    PubMed     Abstract available


  148. JAROLIMOVA J, Yan J, Govere S, Shezi S, et al
    Sexually transmitted infection testing integrated with HIV prevention and contraceptive services in hair salons in urban South Africa.
    J Acquir Immune Defic Syndr. 2025 Apr 7. doi: 10.1097/QAI.0000000000003677.
    PubMed     Abstract available


  149. DUNK CE, Powis KM, Legbedze J, Sun S, et al
    Low placental growth factor levels mid-gestation predict small for gestational age in pregnant women with HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003672.
    PubMed     Abstract available


  150. FISHER SA, Jao J, Yee LM, Serghides L, et al
    Fatty acid signatures in people with HIV: association with adverse pregnancy outcomes and offspring anthropometrics.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003665.
    PubMed     Abstract available


  151. ELBUR AI, Mirzazadeh A, Tate M, Suprasert B, et al
    HIV Incidence among People Who Inject Drugs, San Francisco, 2022.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003673.
    PubMed     Abstract available


  152. EDWARDS KA, Smith KJ, Jones KF, Bair MJ, et al
    Cost-Effectiveness of a Tailored Pain Self-Management Intervention Compared to Enhanced Usual Care Among People with HIV and Chronic Pain: An Economic Evaluation.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003671.
    PubMed     Abstract available


  153. SHARMA A, Hoover DR, Shi Q, Daubert E, et al
    Poor Sleep Quality is Associated with Frailty Among Women with and without HIV.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003668.
    PubMed     Abstract available


  154. GOYAL R, Honerkamp-Smith G, Wells A, Little SJ, et al
    Predictive models to identify individuals with HIV at risk of unsuppressed viral load using routine public health data.
    J Acquir Immune Defic Syndr. 2025 Apr 3. doi: 10.1097/QAI.0000000000003670.
    PubMed     Abstract available


  155. REMERA E, Chammartin F, Nsanzimana S, Malamba SS, et al
    Factors associated with recent HIV infections among newly HIV diagnosed in Rwanda.
    J Acquir Immune Defic Syndr. 2025 Apr 2. doi: 10.1097/QAI.0000000000003669.
    PubMed     Abstract available


  156. WANG RJ, Kunisaki KM, Morris A, Drummond MB, et al
    Brief Report: The Implications of Removing Race From Interpretation of Pulmonary Function Among Persons With or Without HIV.
    J Acquir Immune Defic Syndr. 2025;98:395-400.
    PubMed     Abstract available


  157. TARAMASSO L, Rossotti R, Tavelli A, Santoro MM, et al
    Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort.
    J Acquir Immune Defic Syndr. 2025;98:352-356.
    PubMed     Abstract available


  158. THEODORE DA, Neradilek M, Gillespie K, Edupuganti S, et al
    Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085.
    J Acquir Immune Defic Syndr. 2025;98:340-345.
    PubMed     Abstract available


  159. ZHU X, Patel EU, Berry SA, Grabowski MK, et al
    Brief Report: Trends in Hospital Readmissions Among Adults With and Without HIV in the United States, 2010-2020.
    J Acquir Immune Defic Syndr. 2025;98:334-339.
    PubMed     Abstract available


    March 2025
  160. BUTTS SA, Johnson AL, Doblecki-Lewis S
    PrEP Beyond the Clinic: Evaluation of a Home-Based PrEP Follow-Up System Among a Cohort of Predominantly Black and Latino Men who Have Sex with Men in South Florida.
    J Acquir Immune Defic Syndr. 2025 Mar 28. doi: 10.1097/QAI.0000000000003664.
    PubMed     Abstract available


  161. BANGA J, Nelson BS, Ajibola G, Mohammed T, et al
    Predictive markers for sustained viral suppression on dual bNAbs during ART interruption in children.
    J Acquir Immune Defic Syndr. 2025 Mar 26. doi: 10.1097/QAI.0000000000003663.
    PubMed     Abstract available


  162. KIPTINNESS C, Mugo N, Mugwanya KK, Ngure K, et al
    THE EFFECT OF PARTNER DELIVERY OF HIV SELF-TEST KITS ON HIV TESTING AND LINKAGE TO CARE IN PUBLIC CLINICS IN KENYA.
    J Acquir Immune Defic Syndr. 2025 Mar 26. doi: 10.1097/QAI.0000000000003662.
    PubMed     Abstract available


  163. GUTIERREZ JI JR, Montgomery ET, Dilworth SE, McNulty MC, et al
    Identifying preferred program delivery attributes for long-acting injectable cabotegravir-rilpvirine in three U.S. HIV clinics: A discrete choice experiment.
    J Acquir Immune Defic Syndr. 2025 Mar 13. doi: 10.1097/QAI.0000000000003661.
    PubMed     Abstract available


  164. NJUGUNA I, Moraa H, Mbwayo A, Nyapara F, et al
    "You are the tutor, you are the counselor, you are the school nurse, you are everything": Secondary school staff experience with youth living with HIV.
    J Acquir Immune Defic Syndr. 2025 Mar 11. doi: 10.1097/QAI.0000000000003659.
    PubMed     Abstract available


  165. CHAILLON A, Gaitan NC, Taylor LE, Wu K, et al
    Predictors of Acute HCV Incidence in People with HIV: Insights from a Long-term Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Mar 6. doi: 10.1097/QAI.0000000000003660.
    PubMed     Abstract available


  166. PHILPOTT DC, Curran KG, Russell OO, McClung RP, et al
    HIV Clusters Reported by State and Local Health Departments in the United States, 2020-2022.
    J Acquir Immune Defic Syndr. 2025 Mar 6. doi: 10.1097/QAI.0000000000003658.
    PubMed     Abstract available


  167. DASGUPTA S, Tie Y, Buchacz K, Koenig LJ, et al
    A novel method for assessing poor quality of life among people with HIV.
    J Acquir Immune Defic Syndr. 2025 Mar 5. doi: 10.1097/QAI.0000000000003644.
    PubMed     Abstract available


  168. ZHAO Y, Holtman M, Mudaly V, van Zyl G, et al
    Resistance to Dolutegravir in Treatment-experienced Patients in South Africa: A Retrospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Mar 3. doi: 10.1097/QAI.0000000000003657.
    PubMed     Abstract available


  169. KISTAN G, Sebitloane M, Lombard C, Godlwana Z, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV.
    J Acquir Immune Defic Syndr. 2025;98:265-273.
    PubMed     Abstract available


  170. SMITH MK, Luo D, Meng S, Fei Y, et al
    An Incognito Standardized Patient Approach for Measuring and Reducing Intersectional Healthcare Stigma: A Pilot Cluster Randomized Control Trial.
    J Acquir Immune Defic Syndr. 2025;98:224-233.
    PubMed     Abstract available


  171. VERA M, Sila J, Richardson BA, Otieno F, et al
    Brief Report: Effect of Improved Provider Communication and Adherence to Guidelines on PrEP Initiation in Kisumu Kenya.
    J Acquir Immune Defic Syndr. 2025;98:252-256.
    PubMed     Abstract available


    February 2025
  172. MBENGERANWA T, Ziemba L, Brummel SS, Johnston B, et al
    Bone mineral content, growth, and renal health of infants with perinatal exposure to maternal dolutegravir vs efavirenz and tenofovir disoproxil fumarate vs tenofovir alafenamide: the randomized IMPAACT 2010 (VESTED) trial.
    J Acquir Immune Defic Syndr. 2025 Feb 26. doi: 10.1097/QAI.0000000000003656.
    PubMed     Abstract available


  173. SCONZA R, Fernandes G, Bailey H, Peters H, et al
    Outcomes following prenatal exposure to raltegravir-containing antiretroviral therapy: a multi-cohort European study.
    J Acquir Immune Defic Syndr. 2025 Feb 25. doi: 10.1097/QAI.0000000000003645.
    PubMed     Abstract available


  174. PUTHANAKIT T, Aurpibul L, Lopez M, Wang M, et al
    Efficacy and Safety of the Two-Drug Regimen Dolutegravir/Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-label, Phase 3b Trial.
    J Acquir Immune Defic Syndr. 2025 Feb 24. doi: 10.1097/QAI.0000000000003655.
    PubMed     Abstract available


  175. VINOGRADOV V, Lee YG, Zhakupova G, Mergenova G, et al
    Social Impacts of Multi-City HIV Research Participation Among Sexual and Gender Expansive Individuals in Kazakhstan.
    J Acquir Immune Defic Syndr. 2025 Feb 24. doi: 10.1097/QAI.0000000000003654.
    PubMed     Abstract available


  176. GRAVETT RM, Long DM, Biello KB, Mayer KH, et al
    Preferences for monthly oral PrEP over other PrEP modalities among a national sample of gay, bisexual, and other men who have sex with men in the United States.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003651.
    PubMed     Abstract available


  177. YOUNG J, Wang S, Sacks-Davis R, Stewart A, et al
    Liver fibrosis regression in people living with HIV after successful treatment for hepatitis C.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003646.
    PubMed     Abstract available


  178. LANG R, Coburn SB, Gill MJ, Grossman J, et al
    The Association of Anemia on Non-AIDS Defining Cancer and Subsequent Survival among People with HIV following Antiretroviral Initiation.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003647.
    PubMed     Abstract available


  179. GATHE JC, Dejesus E, Ramgopal MN, Rolle CP, et al
    Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003648.
    PubMed     Abstract available


  180. SHILABYE PS, Scheuermaier K, Vos-Seda AG, Barth RE, et al
    THE ASSOCIATION BETWEEN HIV-RELATED STIGMA, ART ADHERENCE AND CARDIOVASCULAR DISEASE RISK IN PEOPLE LIVING WITH HIV.
    J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003653.
    PubMed     Abstract available


  181. RAMAKRISHNAN A, Goldstein M, Shetty S, Badell M, et al
    Improving Perinatal HIV Care during the COVID-19 Pandemic: Implementing a Mobile Integrated Health Program to Close the Gap.
    J Acquir Immune Defic Syndr. 2025 Feb 13. doi: 10.1097/QAI.0000000000003643.
    PubMed     Abstract available


  182. MOCANU V, Brooks HM, Namasopo S, Opoka RO, et al
    The lived experiences of Ugandan community health workers engaged in prevention of vertical transmission of HIV and a capacity-building intervention.
    J Acquir Immune Defic Syndr. 2025 Feb 13. doi: 10.1097/QAI.0000000000003649.
    PubMed     Abstract available


  183. KOTA KK, Mansergh G, Carnes N, Gelaude D, et al
    Behavioral Readiness for Daily Oral PrEP in a Diverse Sample of Gay, Bisexual, and Other Men who have Sex with Men Who Have Not Been Offered PrEP by a Provider.
    J Acquir Immune Defic Syndr. 2025 Feb 13. doi: 10.1097/QAI.0000000000003650.
    PubMed     Abstract available


  184. ZHENG A, Fox MP, Greener R, Kileel EM, et al
    Initiation of Dolutegravir vs Efavirenz on Viral Suppression and Retention at 6-months: A Regression Discontinuity Design.
    J Acquir Immune Defic Syndr. 2025 Feb 6. doi: 10.1097/QAI.0000000000003642.
    PubMed     Abstract available


  185. SPINELLI MA, Christopoulos KA
    Reply.
    J Acquir Immune Defic Syndr. 2025;98:e12.
    PubMed    


  186. DOMINGUEZ-DOMINGUEZ L, Hamzah L, Fox J, Vincent RP, et al
    Brief Report: Cystatin C Provides Substantially Higher Glomerular Filtration Rate Estimates Than Creatinine in a Subset of Black People With HIV on Current Antiretroviral Regimens.
    J Acquir Immune Defic Syndr. 2025;98:171-175.
    PubMed     Abstract available


  187. TASSIOPOULOS K, John B, Khadraoui A, Salomon L, et al
    Brief Report: Transition Preparation and Post-Transition Evaluation Practices at Adult Clinics That Care for Young Adults With Perinatally Acquired HIV in Massachusetts, United States.
    J Acquir Immune Defic Syndr. 2025;98:103-107.
    PubMed     Abstract available


  188. MAYA S, Sheira LA, Frongillo EA, Pala AN, et al
    Brief Report: Internalized Poverty-Related Stigma and Interpersonal Violence Among Women Living With HIV in the United States.
    J Acquir Immune Defic Syndr. 2025;98:99-102.
    PubMed     Abstract available


    January 2025
  189. MURPHY E, Hoffman S, Ssempijja V, Nalugoda F, et al
    HIV Pre-Exposure Prophylaxis (PrEP) awareness and use among Rakai Community Cohort Study youth aged 15-24.
    J Acquir Immune Defic Syndr. 2025 Jan 31. doi: 10.1097/QAI.0000000000003640.
    PubMed     Abstract available


  190. MARWA MM, Larsen A, Abuna F, Dettinger J, et al
    HIV risk perception and PrEP uptake among pregnant women offered PrEP during antenatal care in Kenya.
    J Acquir Immune Defic Syndr. 2025 Jan 31. doi: 10.1097/QAI.0000000000003641.
    PubMed     Abstract available


  191. MIMIAGA MJ, Kuhns LM, Biello KB, Tian J, et al
    Positive STEPS: Enhancing Medication Adherence and Achieving Viral Load Suppression in Youth Living with HIV in the United States - Results from a Stepped-Care Randomized Controlled Efficacy Trial.
    J Acquir Immune Defic Syndr. 2025 Jan 30. doi: 10.1097/QAI.0000000000003639.
    PubMed     Abstract available


  192. DINIZ CP, Abdul-Massih S, Bagia C, Giguere R, et al
    Rectal Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: An End User Tenofovir Powder Sachet Preparation Feasibility Study (DREAM-04).
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003608.
    PubMed     Abstract available


  193. BAZAZI AR, Thomas M, Vittinghoff E, Walkup J, et al
    Schizophrenia and retention in HIV care among adults insured through Medicaid in the United States: a population-based retrospective cohort study.
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003606.
    PubMed     Abstract available


  194. BAXTER A, Gopalappa C, Islam MH, Viguerie A, et al
    Updates to HIV transmission rate estimates along the HIV care continuum in the United States, 2019.
    J Acquir Immune Defic Syndr. 2025 Jan 23. doi: 10.1097/QAI.0000000000003623.
    PubMed     Abstract available


  195. FISK-HOFFMAN RJ, Liu Y, Somboonwit C, Widmeyer M, et al
    What Matters Most for Long-Acting Antiretroviral Therapy? A Best-Worst Scaling Discrete Choice Experiment.
    J Acquir Immune Defic Syndr. 2025 Jan 21. doi: 10.1097/QAI.0000000000003609.
    PubMed     Abstract available


  196. YU B, Jike C, Lan X, Wang J, et al
    Effect of fertility desire-based service on HIV seroconversion among serodiscordant partners: A 12-year retrospective cohort study.
    J Acquir Immune Defic Syndr. 2025 Jan 21. doi: 10.1097/QAI.0000000000003607.
    PubMed     Abstract available


  197. CALZA L, Colangeli V, Giglia M, Rigamonti C, et al
    EFFICACY AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE IN ANTIRETROVIRAL THERAPY-NAIVE PEOPLE LIVING WITH HIV-1 AND WITH HIGH-LEVEL VIREMIA.
    J Acquir Immune Defic Syndr. 2025 Jan 14. doi: 10.1097/QAI.0000000000003600.
    PubMed     Abstract available


  198. SONG W, Mulatu MS, Crepaz N, Wang G, et al
    Association Between County-Level Social Vulnerability and CDC-funded HIV Testing Program Outcomes in the United States, 2020-2022.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003603.
    PubMed     Abstract available


  199. CARBONE A, Vaccher E, Gloghini A, Pria AD, et al
    Management of KSHV/HHV8 positive Multicentric Castleman Disease concurrent with other KSHV/HHV8 positive disorders. An emergent challenge in PLWH.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003604.
    PubMed    


  200. MARCUS R, Dasgupta S, Taussig J, Tie Y, et al
    Social Determinants of Health and Unmet Needs for Services among Young Adults with HIV: Medical Monitoring Project, 2018-2021.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003605.
    PubMed     Abstract available


  201. CHAN PA, Goedel WC, Li Y, Mena L, et al
    Impact of Social Determinants of Health on Pre-exposure Prophylaxis Care for HIV Prevention.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003601.
    PubMed     Abstract available


  202. JONES J, Siegler AJ, Glick JL, Lucas I, et al
    Potential gains in PrEP coverage and effect on racial disparities following introduction of on-demand and long-acting injectable PrEP: Preferences of men who have sex with men in the United States, 2021-2022.
    J Acquir Immune Defic Syndr. 2025 Jan 9. doi: 10.1097/QAI.0000000000003602.
    PubMed     Abstract available


  203. TESORIERO JM, Boos EM, Adamashvili N, Massaroni R, et al
    Assessing Gaps in Integrated HIV and STI Testing Among New York State-Funded Providers by Pre-Exposure Prophylaxis Status: Implications for Status-Neutral Programming.
    J Acquir Immune Defic Syndr. 2025 Jan 6. doi: 10.1097/QAI.0000000000003598.
    PubMed     Abstract available


  204. HAAS AD, Kusejko K, Cavassini M, Gunthard H, et al
    Late re-engagement into HIV care among adults in the Swiss HIV Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jan 3. doi: 10.1097/QAI.0000000000003597.
    PubMed     Abstract available


  205. MOYLE G, Meng F, Wan H, Sklar P, et al
    Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials.
    J Acquir Immune Defic Syndr. 2025 Jan 3. doi: 10.1097/QAI.0000000000003599.
    PubMed     Abstract available


  206. HORTON RH, Mcintosh A, Ostinelli EG, Harriss E, et al
    Neuropsychiatric Outcomes in Children and Adolescents with Perinatally Acquired HIV: A Systematic Review and Meta Analysis.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003595.
    PubMed     Abstract available


  207. SERUNJOGI R, Mumpe-Mwanja D, Williamson DM, Valencia D, et al
    Risk of adverse birth outcomes and birth defects among women living with HIV on antiretroviral therapy and HIV-negative women in Uganda, 2015-2021.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003596.
    PubMed     Abstract available


  208. L T, F M, D V, S B, et al
    Adherence and forgiveness of two modern ART regimens: lamivudine/dolutegravir and emtricitabine/tenofovir alafenamide/rilpivirine.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003594.
    PubMed     Abstract available


  209. DANG T, Anderson J, Powell AM
    Factors Associated with Retention in HIV Care within 12 months Postpartum: A Retrospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003593.
    PubMed     Abstract available


  210. ANDERSON KM, Sheth AN, Sales JM
    Exploring PrEP Motivation as a Modifiable Target for HIV Prevention Uptake for Cisgender Women in Atlanta, Georgia.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003587.
    PubMed     Abstract available


  211. ANDERSON K, Rabie H, Eley BS, Frigati L, et al
    High incidence of tuberculosis in young children living with HIV in the Western Cape, South Africa.
    J Acquir Immune Defic Syndr. 2025 Jan 2. doi: 10.1097/QAI.0000000000003591.
    PubMed     Abstract available


  212. JALIL CM, Teixeira SLM, Coutinho C, Nazer SC, et al
    Impact of COVID-19 Pandemic on HIV Testing, Recent Infections, and Annualized Incidence Among Cisgender Men Who Have Sex With Men and Transgender Women in Brazil.
    J Acquir Immune Defic Syndr. 2025;98:12-19.
    PubMed     Abstract available


  213. MURPHY M, Rogers B, Galipeau D, Toma E, et al
    HIV Pre-exposure Prophylaxis Use Among Men Experiencing Incarceration in the United States: A Prospective Cohort Study.
    J Acquir Immune Defic Syndr. 2025;98:41-48.
    PubMed     Abstract available


  214. ABRAHAM BK, Vogler M, Talati A, Suresh P, et al
    Pregnancy Outcomes and All-Cause Mortality After Pregnancy Among US-Born Women With Perinatally Acquired HIV.
    J Acquir Immune Defic Syndr. 2025;98:20-28.
    PubMed     Abstract available


  215. HUANG YA, Lowy E, Zhu W, Yu L, et al
    Brief Report: Preexposure Prophylaxis Use Among U.S. Veterans Using Veterans Health Administration Services, 2014 horizontal line 2022.
    J Acquir Immune Defic Syndr. 2025;98:8-11.
    PubMed     Abstract available


    December 2024
  216. GLASS DJ, Kinge M, Njuguna I, McGrath CJ, et al
    Poorer longitudinal growth among HIV exposed compared to unexposed infants in Kenya.
    J Acquir Immune Defic Syndr. 2024 Dec 27. doi: 10.1097/QAI.0000000000003592.
    PubMed     Abstract available


  217. FISHER MC, Hanna DB, Fazzari M, Felsen UR, et al
    Preadmission VACS Index as a Predictor of Hospital Acute Kidney Injury in People with HIV.
    J Acquir Immune Defic Syndr. 2024 Dec 27. doi: 10.1097/QAI.0000000000003589.
    PubMed     Abstract available


  218. ROSENBERG NE, Graybill LA, Mtande T, McGrath N, et al
    The impact of a couple-based intervention on one-year viral suppression among pregnant women living with HIV and their male partners in Malawi: A randomized controlled trial.
    J Acquir Immune Defic Syndr. 2024 Dec 23. doi: 10.1097/QAI.0000000000003583.
    PubMed     Abstract available


  219. BEESHAM I, Jaggernath M, Kriel Y, Hao J, et al
    Longitudinal changes in tenofovir and tenofovir-diphosphate concentrations among pregnant women using oral PrEP for HIV prevention: Findings from Durban, South Africa.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003586.
    PubMed     Abstract available


  220. GUTREUTER S, Denhard L, Logan JE, Blanton J, et al
    Model-Based Prioritization of Adolescent Girls and Young Women for HIV Prevention Services Based on Data from 13 Sub-Saharan African Countries.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003588.
    PubMed     Abstract available


  221. HUANG YA, Chang MH, Zhu W, Hoover KW, et al
    Uptake of HIV Preexposure Prophylaxis Among Medicare Beneficiaries - United States, 2014-2021.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003590.
    PubMed     Abstract available


  222. CHAWKI S, Hamet G, Brun A, Lourenco N, et al
    Pancreatic cancer in people with HIV: a case-control study.
    J Acquir Immune Defic Syndr. 2024 Dec 20. doi: 10.1097/QAI.0000000000003585.
    PubMed     Abstract available


  223. TAN DHS, Antinori A, Eu B, Galindo Puerto MJ, et al
    Weight and metabolic changes with long-acting cabotegravir and rilpivirine or bictegravir/emtricitabine/tenofovir alafenamide.
    J Acquir Immune Defic Syndr. 2024 Dec 16. doi: 10.1097/QAI.0000000000003584.
    PubMed     Abstract available



  224. Early Efficacy and Safety of the Third Dose Inactivated COVID-19 Vaccine Among People Living With HIV: Erratum.
    J Acquir Immune Defic Syndr. 2024;97:e30.
    PubMed    


  225. THORP M, Phiri S, Phiri K, Robson I, et al
    Brief Report: Stated Preferences for Long-Acting Injectable ART Among Mobile Men Living With HIV in Malawi: A Qualitative Study.
    J Acquir Immune Defic Syndr. 2024;97:e25-e29.
    PubMed     Abstract available


  226. HASTIE E, Srivatsa MS, Gianella S, Cottrell M, et al
    Brief Report: Genital Microbiome, Inflammation, and Tenofovir Levels in Transgender Men and Cisgender Women Taking Oral PrEP.
    J Acquir Immune Defic Syndr. 2024;97:477-481.
    PubMed     Abstract available


  227. PAINE EA, Appenroth M, Scheim A, Goldrich M, et al
    Brief Report:Availability of and Interest in Gender-Affirming Care, PrEP, and HIV Prevention Services in a Global Sample of Transmasculine Persons.
    J Acquir Immune Defic Syndr. 2024;97:471-476.
    PubMed     Abstract available


  228. KRENISKE P, Nalugoda F, Chen I, Parate N, et al
    Brief Report: Antiretroviral Treatment Use Over Time Among Adolescents and Young Adults in the Rakai Community Cohort Study, 2011-2020.
    J Acquir Immune Defic Syndr. 2024;97:433-438.
    PubMed     Abstract available


  229. GOLUB SA, Wolfer C, Chastain CA
    INCREASING THE ACCESSIBILITY AND RELEVANCE OF IMPLEMENTATION SCIENCE FOR FRONT-LINE IMPLEMENTERS.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003580.
    PubMed     Abstract available


  230. VOLPI C, Adebiyi R, Chama J, Ononaku U, et al
    Impact of Age of Sexual Debut on HIV Care Engagement among Sexual and Gender Minorities in Nigeria.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003574.
    PubMed     Abstract available


  231. WU L, Ssebuliba T, Muwonge TR, Bambia F, et al
    ALIGNMENT OF PREP USE WITH POTENTIAL HIV EXPOSURE IN YOUNG WOMEN AND MEN IN UGANDA.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003573.
    PubMed     Abstract available


  232. KUGLEN B, Clay C, Boothroyd D, Bennett CL, et al
    Estimated Impact of HIV Testing on Length of Stay at Visits to United States Emergency Departments, 2018-2021.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003575.
    PubMed    


  233. GOLUB SA, Wolfer C, Beacham A, Lane BV, et al
    DEVELOPING A PRACTICE-DRIVEN TAXONOMY OF IMPLEMENTATION STRATEGIES FOR HIV PREVENTION.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003581.
    PubMed     Abstract available


  234. MATTIE H, Goyal R, De Gruttola V, Onnela JP, et al
    A review of network models for HIV spread.
    J Acquir Immune Defic Syndr. 2024 Dec 4. doi: 10.1097/QAI.0000000000003578.
    PubMed     Abstract available


  235. WANG RJ, Kunisaki KM, Morris A, Drummond MB, et al
    The implications of removing race from interpretation of pulmonary function among persons with or without HIV.
    J Acquir Immune Defic Syndr. 2024 Dec 3. doi: 10.1097/QAI.0000000000003579.
    PubMed     Abstract available


  236. MUNROE S, Schackman BR, Madkins K, Saber R, et al
    Economic Evaluation of delivering an evidence-based online HIV prevention program to MSM via direct-to-consumer marketing versus community-based organization recruitment.
    J Acquir Immune Defic Syndr. 2024 Dec 2. doi: 10.1097/QAI.0000000000003572.
    PubMed     Abstract available


  237. HO K, Hoesley C, Anderson PL, Fernandez-Romero JA, et al
    Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037).
    J Acquir Immune Defic Syndr. 2024;97:379-386.
    PubMed     Abstract available


  238. CARNEIRO PB, Radix AE, Golub S, Grosskopf N, et al
    PrEP Use in a US National Sample of Trans Men and Other Transmasculine People Who Have Sex With Men: A Longitudinal Analysis.
    J Acquir Immune Defic Syndr. 2024;97:357-363.
    PubMed     Abstract available


  239. MORGAN E, Punches B, Failla M
    Self-Reported Diagnosis of Autism Is Associated With a Lower Likelihood of HIV Testing.
    J Acquir Immune Defic Syndr. 2024;97:e6-e9.
    PubMed     Abstract available


  240. MATONE M, Piscaglia M, Giacomelli A, Moschese D, et al
    Brief Report: Switching to Long-Acting CAB/RPV: Data From an Italian Monocentric Cohort.
    J Acquir Immune Defic Syndr. 2024;97:e1-e5.
    PubMed     Abstract available


  241. MAYER C, Agbobli-Nuwoaty SE, Li J, Carlson K, et al
    Brief Report: Unmet Need for Solid Organ Transplantation Among People With HIV and End-Stage Kidney or Liver Disease: A Brief Report From the HIV Outpatient Study, 2009-2023.
    J Acquir Immune Defic Syndr. 2024;97:397-401.
    PubMed     Abstract available


  242. WANG Z, Patterson W, Rajulu DT
    Brief Report: Aging With HIV: An Epidemiological Profile of Persons With Diagnosed HIV Aged 50 Years and Older in New York State, 2012-2021.
    J Acquir Immune Defic Syndr. 2024;97:353-356.
    PubMed     Abstract available


    November 2024
  243. KISTAN G, Sebitloane M, Lombard C, Godlwana Z, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 27. doi: 10.1097/QAI.0000000000003563.
    PubMed     Abstract available


  244. DUNN DT, McCabe L, Ward D, Phillips AN, et al
    Assessing whether providing regular, free HIV self-testing kits reduces the time to HIV diagnosis: an internet-based, randomised controlled trial in men who have sex with men.
    J Acquir Immune Defic Syndr. 2024 Nov 22. doi: 10.1097/QAI.0000000000003564.
    PubMed     Abstract available


  245. EGER WH, Shaw LC, Biello KB, Lopez C, et al
    HIV pre-exposure prophylaxis prescription initiation and maintenance among homeless-experienced people who use drugs.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003568.
    PubMed     Abstract available


  246. SMITH MK, Luo D, Meng S, Fei Y, et al
    An Incognito Standardized Patient Approach for Measuring and Reducing Intersectional Healthcare Stigma: A Pilot Cluster Randomized Control Trial.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003565.
    PubMed     Abstract available


  247. DEVANATHAN AS, Poliseno AJ, White NR, Schauer AP, et al
    A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003570.
    PubMed     Abstract available


  248. POWIS KM, Pinilla M, McMorrow F, Stek A, et al
    Pharmacokinetics and safety of bictegravir in pregnant and postpartum persons with HIV and their infants.
    J Acquir Immune Defic Syndr. 2024 Nov 21. doi: 10.1097/QAI.0000000000003571.
    PubMed     Abstract available


  249. MANAVALAN P, Gadkowski LB, Sachdeva A, Guha S, et al
    Acceptability of multi-level sexual health interventions and sexually transmitted infection screening and testing among persons with HIV across three clinical sites in Florida.
    J Acquir Immune Defic Syndr. 2024 Nov 20. doi: 10.1097/QAI.0000000000003569.
    PubMed     Abstract available


  250. YANG X, Cai R, Ma Y, Zhang HH, et al
    Using machine learning techniques to predict viral suppression among people with HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 19. doi: 10.1097/QAI.0000000000003561.
    PubMed     Abstract available


  251. DOS SANTOS FC, Garofalo R, Kuhns L, Scherr T, et al
    Evaluating the Effectiveness of a Mobile Health Intervention on Enhancing HIV Knowledge in Sexual and Gender Minority Men.
    J Acquir Immune Defic Syndr. 2024 Nov 19. doi: 10.1097/QAI.0000000000003562.
    PubMed     Abstract available


  252. PEREZ-BRUMER A, Apedaile D, Leon-Morris F, Huerta L, et al
    Migration is associated with increased HIV vulnerability among young transgender women in Lima, Peru.
    J Acquir Immune Defic Syndr. 2024 Nov 15. doi: 10.1097/QAI.0000000000003560.
    PubMed     Abstract available


  253. ALESSIA S, Sara D, Laura G, Camilla M, et al
    Non-liver malignancies as main cause of mortality after HCV eradication among people living with HIV.
    J Acquir Immune Defic Syndr. 2024 Nov 7. doi: 10.1097/QAI.0000000000003559.
    PubMed     Abstract available


  254. HILL L, Yin J, Patel N, Abulhosn K, et al
    Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine.
    J Acquir Immune Defic Syndr. 2024 Nov 5. doi: 10.1097/QAI.0000000000003556.
    PubMed     Abstract available


  255. HUMPHREY J, Kipchumba B, Alera M, Sang E, et al
    Outcomes After Loss to Follow-Up for Pregnant and Postpartum Women Living With HIV and Their Children in Kenya: A Prospective Cohort Study.
    J Acquir Immune Defic Syndr. 2024;97:242-252.
    PubMed     Abstract available


  256. BAILEY JR, Fonseca E, Borsa A, Hawryluk E, et al
    Three Novel Patient-Reported Outcome Measures to Assess the Patient Experience With Daily and Weekly HIV Oral Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;97:286-295.
    PubMed     Abstract available


  257. AULD SC, Harrington KRV, Nguyen MLT, Colasanti JA, et al
    Brief Report: Alternative Pulmonary Function Measures of Emphysema in People With HIV.
    J Acquir Immune Defic Syndr. 2024;97:282-285.
    PubMed     Abstract available


  258. COMINS CA, Mcingana M, Genberg B, Mulumba N, et al
    Contextual Factors Influencing Implementation of HIV Treatment Support Strategies for Female Sex Workers Living With HIV in South Africa: A Qualitative Analysis Using the Consolidated Framework for Implementation Research.
    J Acquir Immune Defic Syndr. 2024;97:273-281.
    PubMed     Abstract available


  259. LEE CL, Low A, Kreniske P, Mugurungi O, et al
    HIV Outcomes Among Women Living With HIV Who Experienced Early Sexual Violence Across Four Sub-Saharan African Countries.
    J Acquir Immune Defic Syndr. 2024;97:253-260.
    PubMed     Abstract available


  260. CHANDRAN A, Feng X, Coburn SB, Kasaie P, et al
    The Contribution of Socioeconomic Factors to HIV RNA Suppression in Persons With HIV Engaged in Care in the NA-ACCORD.
    J Acquir Immune Defic Syndr. 2024;97:232-241.
    PubMed     Abstract available


  261. ZHABOKRITSKY A, Klein M, Harris M, Loutfy M, et al
    Prevalence and Correlates of Frailty Among Older Adults Living With HIV in the CHANGE HIV Cohort.
    J Acquir Immune Defic Syndr. 2024;97:226-231.
    PubMed     Abstract available


  262. CHAGOMERANA MB, Moser CB, Kang M, Umbleja T, et al
    Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067.
    J Acquir Immune Defic Syndr. 2024;97:216-225.
    PubMed     Abstract available


  263. WULANDARI LPL, Negara SNS, Mashuri YA, Wahyuningtias SD, et al
    A Systematic Review and Meta-analysis of the Impact of the COVID-19 Pandemic on Access to HIV Pre-exposure Prophylaxis: Lessons for Future Public Health Crises.
    J Acquir Immune Defic Syndr. 2024;97:208-215.
    PubMed     Abstract available


  264. HAZIM CE, Coutinho J, Crocker J, Asbjornsdottir K, et al
    Posttrial Experiences in Sustainment of a Scaled Model of the Systems Analysis and Improvement Approach (SAIA-SCALE) in the Absence of External Funding in Manica Province, Mozambique.
    J Acquir Immune Defic Syndr. 2024;97:203-207.
    PubMed     Abstract available


    October 2024
  265. YOUNG R, Ssekasanvu J, Kagaayi J, Ssekubugu R, et al
    HIV and viremia prevalence in non-migrating members of migrant households in southern Uganda: A cross-sectional population-based study.
    J Acquir Immune Defic Syndr. 2024 Oct 31. doi: 10.1097/QAI.0000000000003553.
    PubMed     Abstract available


  266. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on "Prevalence and Correlates of SARS-CoV-2 Vaccine Uptake and Hesitancy Among People With HIV Across the United States".
    J Acquir Immune Defic Syndr. 2024 Oct 30. doi: 10.1097/QAI.0000000000003554.
    PubMed    


  267. TIAMIYU AB, Hu F, Kokogho A, Charurat ME, et al
    Discussion of HIV and Other Sexually Transmitted Infections with Sex Partners of Nigerian Men who have Sex with Men and Transgender Women: Implications for Interventions to Promote Safer Sex Practices.
    J Acquir Immune Defic Syndr. 2024 Oct 24. doi: 10.1097/QAI.0000000000003552.
    PubMed     Abstract available


  268. BERNARD C, Font H, Zotova N, Wools-Kaloustian K, et al
    Accuracy of alternative PHQ-9 scoring algorithms to screen for depression in people living with HIV in Sub-Saharan Africa.
    J Acquir Immune Defic Syndr. 2024 Oct 24. doi: 10.1097/QAI.0000000000003551.
    PubMed     Abstract available


  269. KRIS H, Anders B, Daniela K VS, Kees B, et al
    Hepatitis C treatment and behavioural risk among men who have sex with men with HIV: comparing interferon and direct-acting antiviral eras.
    J Acquir Immune Defic Syndr. 2024 Oct 24. doi: 10.1097/QAI.0000000000003550.
    PubMed     Abstract available


  270. TAIWO BO, Kuhns LM, Agbaji O, David A, et al
    A Stepped-Wedge, Cluster-Randomized, Multisite Study of Text Messaging Plus Peer Navigation to Improve Adherence and Viral Suppression Among Youth on Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024 Oct 18. doi: 10.1097/QAI.0000000000003549.
    PubMed     Abstract available


  271. MAGAGNOLI J, Cummings TH, Wyatt MD, Shtutman M, et al
    Schizophrenia, Off-Label Antipsychotics, and Dementia Risk in People with HIV.
    J Acquir Immune Defic Syndr. 2024 Oct 17. doi: 10.1097/QAI.0000000000003545.
    PubMed     Abstract available


  272. ROGERS B, Ramsey S, Ames E, Gomes N, et al
    Addressing barriers to implementing and scaling PrEP in carceral settings: Applying insights from implementation science.
    J Acquir Immune Defic Syndr. 2024 Oct 10. doi: 10.1097/QAI.0000000000003547.
    PubMed     Abstract available


  273. RACCAGNI AR, Passini F, Diotallevi S, Lolatto R, et al
    Gaps in HIV Pre-exposure Prophylaxis Acceptance: Findings from an Outpatient HIV Testing Service in Italy.
    J Acquir Immune Defic Syndr. 2024 Oct 8. doi: 10.1097/QAI.0000000000003544.
    PubMed     Abstract available


  274. FINN B, Vanessa M, Xochitl LM, Emily P, et al
    Addressing methamphetamine use is essential to stopping HIV transmission.
    J Acquir Immune Defic Syndr. 2024 Oct 7. doi: 10.1097/QAI.0000000000003542.
    PubMed    


  275. KOTA KK, Eppink S, Gant Z, Chesson H, et al
    Racial and Ethnic Disparities in HIV Diagnosis Rates by Social Determinants of Health at the Census Tract Level among Adults in the United States and Puerto Rico, 2021.
    J Acquir Immune Defic Syndr. 2024 Oct 4. doi: 10.1097/QAI.0000000000003541.
    PubMed     Abstract available


  276. BURNETT J, Olansky E, Baugher AR, Lee K, et al
    Intersecting structural and psychosocial conditions: investigating injection drug use and HIV among transgender women.
    J Acquir Immune Defic Syndr. 2024 Oct 4. doi: 10.1097/QAI.0000000000003543.
    PubMed     Abstract available


  277. COLER B, Smith GH, Arora AK, Wells A, et al
    Quality of Life in People with HIV at the End of Life: Preliminary Results from the Last Gift Observational Cohort Study.
    J Acquir Immune Defic Syndr. 2024 Oct 3. doi: 10.1097/QAI.0000000000003536.
    PubMed     Abstract available



  278. Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    J Acquir Immune Defic Syndr. 2024;97:202.
    PubMed    


  279. ORR JE, Velazquez J, Schmickl CN, Bosompra NO, et al
    Sleep, Sleep Apnea, and Fatigue in People Living With HIV.
    J Acquir Immune Defic Syndr. 2024;97:192-201.
    PubMed     Abstract available


  280. LAZZARO A, Vai D, Barco A, Stroffolini G, et al
    Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2024;97:180-191.
    PubMed     Abstract available


  281. MASHETO G, Brummel SS, Ziemba L, Shepherd J, et al
    Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial.
    J Acquir Immune Defic Syndr. 2024;97:172-179.
    PubMed     Abstract available


  282. DEBROY P, Barrett BW, Erlandson KM, Budoff M, et al
    Relationships Between Hepatic Steatosis and Frailty Differ by HIV Serostatus.
    J Acquir Immune Defic Syndr. 2024;97:165-171.
    PubMed     Abstract available


  283. AOUIZERAT BE, Garcia JN, Domingues CV, Xu K, et al
    Frequent Cocaine Use is Associated With Larger HIV Latent Reservoir Size.
    J Acquir Immune Defic Syndr. 2024;97:156-164.
    PubMed     Abstract available


  284. BELTRAN RM, Hunter LA, Packel LJ, De Martini L, et al
    A Mixed Methods Evaluation of Pharmacists' Readiness to Provide Long-Acting Injectable HIV Pre-exposure Prophylaxis in California.
    J Acquir Immune Defic Syndr. 2024;97:142-149.
    PubMed     Abstract available


  285. MACGOWAN RJ, Chavez PR, Dana R, Hannah M, et al
    Efficacy of Internet Recruitment and HIV Self-Testing for Diagnosing HIV Infections Among Black and Hispanic/Latino MSM and Transgender Women in 11 US States, 2020-2021.
    J Acquir Immune Defic Syndr. 2024;97:133-141.
    PubMed     Abstract available


  286. MUJUGIRA A, Karungi B, Nakyanzi A, Bagaya M, et al
    Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial.
    J Acquir Immune Defic Syndr. 2024;97:125-132.
    PubMed     Abstract available


  287. MCDONALD SA, Yeung A, Nandwani R, Clutterbuck D, et al
    A Statistical Model for Inference of Recent and Incident HIV Infection Using Surveillance Data on Individuals Newly Diagnosed With HIV Infection in Scotland.
    J Acquir Immune Defic Syndr. 2024;97:117-124.
    PubMed     Abstract available


  288. YANG X, Zhang J, Chen S, Liu Z, et al
    COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis.
    J Acquir Immune Defic Syndr. 2024;97:107-116.
    PubMed     Abstract available


  289. YIGIT I, Budhwani H, Rainer CB, Claude K, et al
    Associations Between PrEP Stigma, PrEP Confidence, and PrEP Adherence: Conditional Indirect Effects of Anticipated HIV Stigma.
    J Acquir Immune Defic Syndr. 2024;97:99-106.
    PubMed     Abstract available


  290. OKEGBE T, Bishop KM, Rose J, Srivastava M, et al
    Trends in the Uptake of Index Testing among Adolescents in USAID-Supported PEPFAR Programs, October 2017- September 2022.
    J Acquir Immune Defic Syndr. 2024 Oct 1. doi: 10.1097/QAI.0000000000003540.
    PubMed     Abstract available


  291. FAIRLIE L, Brummel S, Ziemba L, Coletti A, et al
    Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV.
    J Acquir Immune Defic Syndr. 2024;97:150-155.
    PubMed     Abstract available


    September 2024
  292. HONG HANH NT, Phuong Tram PT, Thanh Ha HT, Duc BH, et al
    Detection of antiretroviral drug-resistant mutations and HIV-1 subtypes in circulation among men who have sex with men, SEM females and female sex workers: results of Vietnam's HIV Sentinel Surveillance Plus (HSS+) system, 2018 - 2020.
    J Acquir Immune Defic Syndr. 2024 Sep 26. doi: 10.1097/QAI.0000000000003537.
    PubMed     Abstract available


  293. EDELMAN EJ, Dziura J, Deng Y, DePhilippis D, et al
    Integrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial.
    J Acquir Immune Defic Syndr. 2024 Sep 25. doi: 10.1097/QAI.0000000000003534.
    PubMed     Abstract available


  294. GUTEMA Y, Lulseged S, Getachew M, Getahun M, et al
    Index-linked Assisted HIV Self-Testing for Children 2-14 Years: Results of a Pilot Evaluation in Ethiopia.
    J Acquir Immune Defic Syndr. 2024 Sep 25. doi: 10.1097/QAI.0000000000003533.
    PubMed     Abstract available


  295. ZINGONI ZM, Okano JT, Ponce J, Dullie L, et al
    Modeling travel-time to HIV treatment in Malawi: identifying rural-urban and wealth inequities.
    J Acquir Immune Defic Syndr. 2024 Sep 24. doi: 10.1097/QAI.0000000000003539.
    PubMed    


  296. JALIL CM, Maia Teixeira SL, Coutinho C, Nazer SC, et al
    Impact of Covid-19 pandemic on HIV testing, recent infections and annualized incidence among cisgender men who have sex with men and transgender women in Brazil.
    J Acquir Immune Defic Syndr. 2024 Sep 18. doi: 10.1097/QAI.0000000000003531.
    PubMed     Abstract available


  297. SELZER L, VanderVeen LA, Parvangada A, Martin R, et al
    Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People with HIV-1 Suppressed by Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024 Sep 18. doi: 10.1097/QAI.0000000000003528.
    PubMed     Abstract available


  298. ANGULIQUE O, Thomas T, Karen M, Monique J, et al
    Motivational Enhancement System for Adherence (MESA) for Adolescents and Young Adults Newly Recommended to Start Antiretroviral Therapy (ART).
    J Acquir Immune Defic Syndr. 2024 Sep 17. doi: 10.1097/QAI.0000000000003530.
    PubMed     Abstract available


  299. CORBETT C, van Rensburg R, Brey N, O'Hagan S, et al
    Timing of ART initiation associated with HIV-associated stroke.
    J Acquir Immune Defic Syndr. 2024 Sep 17. doi: 10.1097/QAI.0000000000003529.
    PubMed    


  300. WEIJSENFELD A, van der Knaap L, Sattoe J, van Staa A, et al
    Health-related quality of life in young adults with perinatal HIV after transfer to adult health care in the Netherlands.
    J Acquir Immune Defic Syndr. 2024 Sep 12. doi: 10.1097/QAI.0000000000003526.
    PubMed     Abstract available


  301. REISNER SL, Humes E, Stevenson M, Cooney EE, et al
    Site-based and Digital Cohort Participation Among Transgender Women in the Eastern and Southern USA: Findings from the LITE Study.
    J Acquir Immune Defic Syndr. 2024 Sep 12. doi: 10.1097/QAI.0000000000003527.
    PubMed     Abstract available


  302. MICHAEL HU, Brouillette MJ, Tamblyn R, Fellows LK, et al
    Disentangling the Effects of Comorbidity and Polypharmacy on Cognitive Function and Physical Frailty in Individuals with HIV.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003523.
    PubMed     Abstract available


  303. BELL GJ, Chen JS, Maierhofer CN, Matoga M, et al
    Updated Risk Score Algorithms for Acute HIV Infection Detection at a Sexually Transmitted Infections Clinic in Lilongwe, Malawi.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003519.
    PubMed     Abstract available


  304. DEJESUS E, Towner WJ Jr, Gathe JC, Cash RB, et al
    Efficacy and safety of two fixed doses of ibalizumab plus optimized background regimen in treatment-experienced HIV-positive individuals.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003524.
    PubMed     Abstract available


  305. EL-HIBRI F, Al-Hindawi A, Singh S, Bower M, et al
    Outcomes of lymphoma patients admitted to the ICU are not influenced by HIV status: a retrospective, observational cohort study.
    J Acquir Immune Defic Syndr. 2024 Sep 9. doi: 10.1097/QAI.0000000000003522.
    PubMed     Abstract available


  306. BATOHI N, Shalekoff S, Martinson NA, Ebrahim O, et al
    HIV-1 Elite Controllers are Characterised by Elevated Levels of CD69-Expressing Natural Killer Cells.
    J Acquir Immune Defic Syndr. 2024 Sep 2. doi: 10.1097/QAI.0000000000003518.
    PubMed     Abstract available


  307. DA CUNHA GH, Fontenele MSM, Galvao MTG, Dantas MB, et al
    Factors Associated With Symptoms of Anxiety and Depression in People Living With HIV in Northeast Brazil.
    J Acquir Immune Defic Syndr. 2024;97:87-98.
    PubMed     Abstract available


  308. BERNARD I, Ransy DG, Brophy J, Kakkar F, et al
    Lower Neutrophil Count Without Clinical Consequence Among Children of African Ancestry Living With HIV in Canada.
    J Acquir Immune Defic Syndr. 2024;97:78-86.
    PubMed     Abstract available


  309. PENCE BW, Darnell D, Ranna-Stewart M, Psaros C, et al
    Provocative Findings From a Transdiagnostic Counseling Intervention to Improve Psychiatric Comorbidity and HIV Care Engagement Among People With HIV: A Pilot Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2024;97:68-77.
    PubMed     Abstract available


  310. DEROSE KP, Palar K, Then-Paulino A, Han B, et al
    Changes in HIV Internalized and Experienced Stigmas and Social Support After an Urban Gardens and Peer Nutritional Counseling Intervention Among People With HIV and Food Insecurity in the Dominican Republic.
    J Acquir Immune Defic Syndr. 2024;97:55-62.
    PubMed     Abstract available


  311. FULTON J, Novitsky V, Gillani F, Guang A, et al
    Integrating HIV Cluster Analysis in Everyday Public Health Practice: Lessons Learned From a Public Health--Academic Partnership.
    J Acquir Immune Defic Syndr. 2024;97:48-54.
    PubMed     Abstract available


  312. NETHI AK, Karam AG, Alvarez KS, Luque AE, et al
    Using Machine Learning to Identify Patients at Risk of Acquiring HIV in an Urban Health System.
    J Acquir Immune Defic Syndr. 2024;97:40-47.
    PubMed     Abstract available


  313. ROGERS BG, Toma E, Harkness A, Arnold T, et al
    "Why Not Just go on PrEP?": A Study to Inform Implementation of an HIV Prevention Intervention Among Hispanic/Latino Men Who Have Sex With Men in the Northeastern United States.
    J Acquir Immune Defic Syndr. 2024;97:26-39.
    PubMed     Abstract available


  314. SPINELLI MA, Johnson MO, Lisha NE, Jain JP, et al
    Prevalence and Correlates of SARS-CoV-2 Vaccine Uptake and Hesitancy Among People With HIV Across the United States.
    J Acquir Immune Defic Syndr. 2024;97:13-18.
    PubMed     Abstract available


  315. UNTERNAHER J, Koay WLA, Mareuil J, Williams T, et al
    Progress in Eliminating Perinatal HIV Transmission in the Metropolitan DC Area Between 2018-2022.
    J Acquir Immune Defic Syndr. 2024;97:6-12.
    PubMed     Abstract available


  316. YAN CY, Cooley SA, Ances BM
    Veterans Aging Cohort Study Index 2.0 Shows Improved Discrimination of Neurocognitive Impairment and Frailty in People with HIV.
    J Acquir Immune Defic Syndr. 2024;97:63-67.
    PubMed     Abstract available


  317. COONEY EE, Reisner SL, Poteat TC, Althoff KN, et al
    Brief Report: Interest in Long-acting Injectable PrEP Among Transgender Women in Eastern and Southern United States.
    J Acquir Immune Defic Syndr. 2024;97:19-25.
    PubMed     Abstract available


  318. SIMMS V, Kranzer K, Dziva Chikwari C, Dauya E, et al
    Brief Report: Youth Who Acquired HIV Perinatally Have Poorer Viral Suppression Than Those Who Acquired HIV Later in Life: Findings From a Population Survey in Zimbabwe.
    J Acquir Immune Defic Syndr. 2024;97:1-5.
    PubMed     Abstract available


    August 2024
  319. WALTERS MK, Korenromp EL, Yakusik A, Wanyeki I, et al
    Guidance for triangulating data and estimates of HIV prevalence among pregnant women and coverage of PMTCT using the Spectrum AIDS Impact Module.
    J Acquir Immune Defic Syndr. 2024 Aug 27. doi: 10.1097/QAI.0000000000003514.
    PubMed     Abstract available


  320. REITSEMA M, Wallinga J, van Sighem AI, Bezemer D, et al
    Impact of varying pre-exposure prophylaxis programs on HIV and Neisseria gonorrhoeae transmission among MSM in the Netherlands: a modelling study.
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003511.
    PubMed     Abstract available


  321. JOHN SA, Walsh JL, Doherty RM, Rine SR, et al
    Determinants of potential HIV vaccine uptake among young sexual minoritized men 17-24 years old.
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003517.
    PubMed     Abstract available


  322. MBABAZI P, Chen G, Ritchie CS, Tsai AC, et al
    Prevalence and correlates of frailty among older people with and without HIV in rural Uganda.
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003513.
    PubMed     Abstract available


  323. JIAMSAKUL A, Rupasinghe D, Woolley I, Choi JY, et al
    HIV treatment outcomes after 10 years on ART in the TREAT Asia Observational Database (TAHOD) and Australian HIV Observational Database (AHOD).
    J Acquir Immune Defic Syndr. 2024 Aug 22. doi: 10.1097/QAI.0000000000003515.
    PubMed     Abstract available


  324. NALINTYA E, Sekar P, Namakula OL, Tadeo KK, et al
    The diagnostic performance of the Visitect Advanced Disease point-of-care CD4 platform: a pragmatic mixed-methods multisite validation, costing, and qualitative analysis.
    J Acquir Immune Defic Syndr. 2024 Aug 19. doi: 10.1097/QAI.0000000000003505.
    PubMed     Abstract available


  325. MSOSA TC, Swai I, Aarnoutse R, Rinke de Wit TF, et al
    The Effect of Real-Time Medication Monitoring-Based Digital Adherence Tools on Adherence to Antiretroviral Therapy and Viral Suppression in People Living With HIV: A Systematic Literature Review and Meta-Analysis.
    J Acquir Immune Defic Syndr. 2024;96:411-420.
    PubMed     Abstract available


  326. SHORER EF, Dastgheyb RM, French AL, Daubert E, et al
    Tryptophan-Kynurenine Pathway Activation and Cognition in Virally Suppressed Women With HIV.
    J Acquir Immune Defic Syndr. 2024;96:494-500.
    PubMed     Abstract available


  327. MARTIN TCS, Smith LR, Anderson C, Little SJ, et al
    Randomized Controlled Trial of 60 minutes for Health With Rapid Antiretroviral Therapy to Reengage Persons With HIV Who Are Out of Care.
    J Acquir Immune Defic Syndr. 2024;96:486-493.
    PubMed     Abstract available


  328. JONSSON-OLDENBUTTEL C, Ghosn J, van der Valk M, Florence E, et al
    Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
    J Acquir Immune Defic Syndr. 2024;96:472-480.
    PubMed     Abstract available


  329. HOFFMANN CJ, Herce ME, Chimoyi L, Smith HJ, et al
    Reaching for 90:90:90 in Correctional Facilities in South Africa and Zambia: Virtual Cross-Section of Coverage of HIV Testing and Antiretroviral Therapy During Universal Test and Treat Implementation.
    J Acquir Immune Defic Syndr. 2024;96:465-471.
    PubMed     Abstract available


  330. ROY PALADHI U, Katz DA, Otieno G, Hughes JP, et al
    Effectiveness of Using Additional HIV Self-Test Kits as an Incentive to Increase HIV Testing Within Assisted Partner Services.
    J Acquir Immune Defic Syndr. 2024;96:457-464.
    PubMed     Abstract available


  331. NICOLAU IA, Moineddin R, Brooks JD, Antoniou T, et al
    Associations of CD4 Cell Count Measures With Infection-Related and Infection-Unrelated Cancer Risk Among People With HIV.
    J Acquir Immune Defic Syndr. 2024;96:447-456.
    PubMed     Abstract available


  332. HERNANDEZ AL, Hilton JF, Weatherly CS, Berry-Lawhorn JM, et al
    Prevalence of Anal Human Papillomavirus Infection and Anal High-Grade Squamous Intraepithelial Lesions Among Men Who Have Sex With Men 50 Years and Older Living With or Without HIV.
    J Acquir Immune Defic Syndr. 2024;96:439-446.
    PubMed     Abstract available


  333. BARTH SK, Monroe AK, Houston P, Benator D, et al
    COVID-19 Incidence, Risk Factors, Impact, and Related Stigma Among a Cohort of Persons With HIV in Washington, DC.
    J Acquir Immune Defic Syndr. 2024;96:429-438.
    PubMed     Abstract available


  334. SAVINELLI S, McGettrick P, Garcia Leon AA, Tinago W, et al
    Obesity is associated with higher levels of circulating cytokines involved in the development of cardiovascular disease in people living with HIV.
    J Acquir Immune Defic Syndr. 2024 Aug 15. doi: 10.1097/QAI.0000000000003508.
    PubMed     Abstract available


  335. RUSSELL ES, Zhou M, Song Y, Barak N, et al
    Patterns of HIV treatment preferences among people with diverse demographic, social, and behavioral characteristics who are living with HIV in the United States.
    J Acquir Immune Defic Syndr. 2024 Aug 15. doi: 10.1097/QAI.0000000000003509.
    PubMed     Abstract available


  336. ISLAS-MUNOZ B, Chavez-Galan L, Ramon-Luing L, Flores-Gonzalez J, et al
    Comparison of IL-6, IL-10, and TNFalpha levels between PLWHIV with and without Kaposi Sarcoma and healthy controls.
    J Acquir Immune Defic Syndr. 2024 Aug 15. doi: 10.1097/QAI.0000000000003507.
    PubMed     Abstract available


  337. CYKTOR JC, Yeh E, Ribaudo H, Hoeth D, et al
    Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection.
    J Acquir Immune Defic Syndr. 2024;96:481-485.
    PubMed     Abstract available


  338. ROSS JL, Teeraananchai S, Avihingsanon A, Lee MP, et al
    Brief Report: Depression, Substance Use, and Factors Associated With Sexual Risk Behaviors Among Adults Living With HIV in the Asia-Pacific Region.
    J Acquir Immune Defic Syndr. 2024;96:421-428.
    PubMed     Abstract available


  339. MISTRI P, Tomescu S, Bokolo S, De Nooy A, et al
    Evaluation of four interventions using behavioural economics insights to increase demand for voluntary medical male circumcision in South Africa through the MoyaApp: A quasi-experimental study.
    J Acquir Immune Defic Syndr. 2024 Aug 9. doi: 10.1097/QAI.0000000000003504.
    PubMed     Abstract available


  340. LANG R, Coburn SB, Gill MJ, Grossman J, et al
    THE ASSOCIATION OF ANEMIA WITH SURVIVAL AMONG PEOPLE WITH HIV FOLLOWING ANTIRETROVIRAL INITIATION IN THE NA-ACCORD 2007-2016.
    J Acquir Immune Defic Syndr. 2024 Aug 9. doi: 10.1097/QAI.0000000000003502.
    PubMed     Abstract available


  341. LUC CM, Max B, Perez S, Herrera K, et al
    Acceptability of Long-Acting Cabotegravir + Rilpivirine in a Large, Urban, Ambulatory HIV Clinic.
    J Acquir Immune Defic Syndr. 2024 Aug 5. doi: 10.1097/QAI.0000000000003500.
    PubMed     Abstract available


  342. LIPPMAN SA, Grignon JS, Ditshwane B, West RL, et al
    Results of the Sukuma Ndoda ("Stand up, Man") HIV Self-Screening and Assisted Linkage to Care Project in Johannesburg: A Quasi-Experimental Pre-Post Evaluation.
    J Acquir Immune Defic Syndr. 2024;96:367-375.
    PubMed     Abstract available


  343. GARRETT N, Dintwe O, Monaco CL, Jones M, et al
    Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.
    J Acquir Immune Defic Syndr. 2024;96:350-360.
    PubMed     Abstract available


  344. HALLARN J, Scheim AI, Bauer GR
    Pre-exposure Prophylaxis Awareness and Use Among Transgender and Nonbinary Individuals in Canada.
    J Acquir Immune Defic Syndr. 2024;96:341-349.
    PubMed     Abstract available


  345. ROHR JK, Manne-Goehler J, Gomez-Olive FX, Kahn K, et al
    The HIV Care Cascade for Older Adults in Rural South Africa: A Longitudinal Cohort Study (2014-2019).
    J Acquir Immune Defic Syndr. 2024;96:334-340.
    PubMed     Abstract available


  346. ROSEN AD, Javanbakht M, Shoptaw SJ, Seamans MJ, et al
    Associations of Sleep Deficiency With Sexual Risk Behaviors and HIV Treatment Outcomes Among Men Who Have Sex With Men Living With or at High Risk of Acquiring HIV.
    J Acquir Immune Defic Syndr. 2024;96:326-333.
    PubMed     Abstract available


  347. TSENG AS, Mugwanya KK, Szpiro AA, van Heerden A, et al
    Estimating the Effect of COVID-19 Pandemic Restrictions on Self-reported Antiretroviral Therapy Use and Late Refill Visits Among People Living With HIV in Rural South Africa.
    J Acquir Immune Defic Syndr. 2024;96:318-325.
    PubMed     Abstract available



  348. Effectiveness of PrEPTECH: Findings From a 180-Day Randomized Controlled Trial of a Pre-Exposure Prophylaxis Telehealth Intervention: Erratum.
    J Acquir Immune Defic Syndr. 2024;96:410.
    PubMed    


  349. MORRISON S, Batting J, Wanga V, Beesham I, et al
    True and false positive HIV point of care test results in a prospective multinational study of at-risk African women: implications for large-scale repeat HIV testing in HIV prevention programs.
    J Acquir Immune Defic Syndr. 2024 Aug 1. doi: 10.1097/QAI.0000000000003497.
    PubMed     Abstract available


  350. FOLEY JD, Bernier LB, Ngo L, Batchelder AW, et al
    Evaluating the Efficacy of Psycho-Behavioral Interventions for Cardiovascular Risk among People Living with HIV: A Systematic Review and Meta-Synthesis of Randomized Controlled Trials.
    J Acquir Immune Defic Syndr. 2024;96:399-409.
    PubMed     Abstract available


  351. BISHOP MD, Korutaro V, Boyce CL, Beck IA, et al
    Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.
    J Acquir Immune Defic Syndr. 2024;96:385-392.
    PubMed     Abstract available


  352. NEARY J, Njuguna I, Wagner AD, Richardson BA, et al
    Brief Report: Group-Based Trajectory Modeling to Determine Long-Term HIV Viral Load Trends Among Children With HIV in Kenya.
    J Acquir Immune Defic Syndr. 2024;96:311-317.
    PubMed     Abstract available


  353. TUKEI VJ, Machekano R, Tchounga BK, Khumalo PN, et al
    Follow-up Outcomes of Children, Adolescents and Young People on Darunavir-Based Third-line Antiretroviral Therapy - Observational Cohort from Nine African Countries.
    J Acquir Immune Defic Syndr. 2024 Aug 1. doi: 10.1097/QAI.0000000000003498.
    PubMed     Abstract available


  354. COBURN SB, Pimentel N, Leyden W, Kitahata M, et al
    Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV.
    J Acquir Immune Defic Syndr. 2024;96:393-398.
    PubMed     Abstract available


  355. D'ANTONI ML, Andreatta K, Chang S, Cox S, et al
    Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
    J Acquir Immune Defic Syndr. 2024;96:380-384.
    PubMed     Abstract available


  356. PHOGOLE CM, Bekker A, Cressey TR, Ferris W, et al
    Brief Report: Can a Fraction of the Dolutegravir Dispersible Tablet Solution be Used to Dose Neonates?
    J Acquir Immune Defic Syndr. 2024;96:376-379.
    PubMed     Abstract available


    July 2024
  357. LEONG TD, Nel J, Jamieson L, Osih R, et al
    A review and economic analysis of the dapivirine vaginal ring as HIV pre-exposure prophylaxis for women, to inform South African public-sector guidelines.
    J Acquir Immune Defic Syndr. 2024 Jul 25. doi: 10.1097/QAI.0000000000003496.
    PubMed     Abstract available


  358. SINGOGO E, Weir SS, Kudowa E, Chagomerana M, et al
    Characterising HIV acquisition risk, treatment gaps and populations reached through venue-based outreach and clinical services in Blantyre, Malawi: findings from a district-wide CLOVE Study.
    J Acquir Immune Defic Syndr. 2024 Jul 18. doi: 10.1097/QAI.0000000000003493.
    PubMed     Abstract available


  359. MCCRIMMON T, Collins LF, Pereyra M, Platamone C, et al
    Likelihood of Trying Long-Acting Injectable Antiretroviral Therapy Among Women With HIV in Nine Sites Across the United States.
    J Acquir Immune Defic Syndr. 2024;96:e23-e27.
    PubMed    


  360. OYUGA R, Amadi E, Blanco N, Ndaga A, et al
    Effects of Multimonth Dispensing on Viral Suppression and Continuity in Treatment Among Children Living With HIV Aged 2-9 Years: A Cohort Study in Western Kenya.
    J Acquir Immune Defic Syndr. 2024;96:290-298.
    PubMed     Abstract available


  361. CALABRESE SK, Zaheer MA, Flores JJ, Kalwicz DA, et al
    Messaging About HIV Transmission Risk When Viral Load Is Undetectable: Reactions and Perceived Accuracy Among US Sexual Minority Men.
    J Acquir Immune Defic Syndr. 2024;96:270-279.
    PubMed     Abstract available


  362. AUDET CM, Graves E, Shepherd BE, Prigmore HL, et al
    Partner-Based HIV Treatment for Seroconcordant Couples Attending Antenatal and Postnatal Care in Rural Mozambique: A Cluster Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2024;96:259-269.
    PubMed     Abstract available


  363. VITRUK O, Ihnatiuk AP, Kazanzhy AP, Shvab M, et al
    Uptake and Persistent Use of HIV Preexposure Prophylaxis Among Key Populations: Results From Ukraine's Scaled National Preexposure Prophylaxis Program.
    J Acquir Immune Defic Syndr. 2024;96:241-249.
    PubMed     Abstract available


  364. BAKOYANNIS G, Elul B, Wools-Kaloustian KK, Brown S, et al
    Modeling the HIV Cascade of Care Using Routinely Collected Clinical Data to Guide Programmatic Interventions and Policy Decisions.
    J Acquir Immune Defic Syndr. 2024;96:223-230.
    PubMed     Abstract available


  365. PETERS BA, Hanna DB, Xue X, Weber K, et al
    Menopause and Estrogen Associations With Gut Barrier, Microbial Translocation, and Immune Activation Biomarkers in Women With and Without HIV.
    J Acquir Immune Defic Syndr. 2024;96:214-222.
    PubMed     Abstract available


  366. CHOI J, May SB, Dang BN, Markham C, et al
    Acceptability of a Future HIV Vaccine: A Rapid Scoping Review.
    J Acquir Immune Defic Syndr. 2024;96:197-207.
    PubMed     Abstract available


    June 2024
  367. DIRAJLAL-FARGO S, Sattar A, Strah M, Karungi C, et al
    Immune activation is associated with neurocognitive performance in Ugandan Adolescents living with HIV.
    J Acquir Immune Defic Syndr. 2024 Jun 21. doi: 10.1097/QAI.0000000000003483.
    PubMed     Abstract available



  368. Short-term Outcomes From a Cluster Randomized Evaluation of Adherence Clubs as Part of Differentiated HIV Care in South Africa: Retraction.
    J Acquir Immune Defic Syndr. 2024;96:e14.
    PubMed    



  369. Perception and Emotional Experiences of Infant Feeding Among Women Living With HIV in a High-Income Setting: A Longitudinal Mixed Methods Study: Erratum.
    J Acquir Immune Defic Syndr. 2024;96:e12-e13.
    PubMed    


  370. IANNONE V, Ciccullo A, Moschese D, Giacomelli A, et al
    Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort.
    J Acquir Immune Defic Syndr. 2024;96:e10-e11.
    PubMed    


  371. JI C, Chen L, Kaypaghian M
    Effects of Combination of Ethanol With Ritonavir, Lopinavir or Darunavir on Expression and Localization of the ER-Associated Set Protein and Infection of HIV-1 Pseudovirus in Primary Human Cells.
    J Acquir Immune Defic Syndr. 2024;96:e6-e10.
    PubMed    


  372. BENNETT CL, Saxena M, Boothroyd D, Mahmoud-Werthmann S, et al
    Association Between Social Vulnerability and US HIV Priority Jurisdictions.
    J Acquir Immune Defic Syndr. 2024;96:e4-e6.
    PubMed    


  373. ZHOU S, Cluver L, Knight L, Edun O, et al
    Longitudinal Trajectories of Antiretroviral Treatment Adherence and Associations With Durable Viral Suppression Among Adolescents Living With HIV in South Africa.
    J Acquir Immune Defic Syndr. 2024;96:171-179.
    PubMed     Abstract available


  374. WHITE DAE, Godoy A, Jewett M, Burns M, et al
    Outcomes of an Emergency Department Program to Identify and Link Patients at Increased Risk for Acquiring HIV Infection to Outpatient HIV Prevention Services: The HIV PreventED Program.
    J Acquir Immune Defic Syndr. 2024;96:147-155.
    PubMed     Abstract available


  375. ROSENTHAL M, Patterson W, Rajulu DT
    Missed Opportunities: Characteristics of People Who Received a Concurrent HIV/AIDS Diagnosis in New York State From 2016 to 2021.
    J Acquir Immune Defic Syndr. 2024;96:130-135.
    PubMed     Abstract available


  376. BECKER M, Mishra S, Bhattacharjee P, Musyoki H, et al
    Differential Burden of HIV Among Adolescent Girls and Young Women by Places Associated With Sex Work: An Observational Study in Mombasa, Kenya.
    J Acquir Immune Defic Syndr. 2024;96:121-129.
    PubMed     Abstract available



  377. Short-Term Outcomes From a Cluster Randomized Evaluation of Adherence Clubs as Part of Differentiated HIV Care in South Africa [RETRACTED].
    J Acquir Immune Defic Syndr. 2024;96:e15-e22.
    PubMed    


  378. WANDIKA B, Nyapara F, Aballa C, Richardson BA, et al
    Lower self-reported ART adherence among adolescents in boarding schools compared to day schools.
    J Acquir Immune Defic Syndr. 2024;96:101-105.
    PubMed     Abstract available


    May 2024

  379. Time to Treatment Initiation and HIV Viral Suppression in People Diagnosed With HIV-1 During COVID-19 Pandemic in Ex-Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliCOV Study): Erratum.
    J Acquir Immune Defic Syndr. 2024;96:e3.
    PubMed    


  380. RAMBIKI E, Rambiki K, Khalani J, Huwa J, et al
    Letters to the Editor Low Rates of Side Effects in Paclitaxel Chemotherapy for Kaposi Sarcoma and Feasibility of Treatment in Outpatient ART Clinic Settings in Malawi.
    J Acquir Immune Defic Syndr. 2024;96:e1-e2.
    PubMed    


  381. WELD ED, Ogasawara K, Fuchs EJ, Louissaint N, et al
    Mapping Colorectal Distribution of Cell-free and Cell-associated HIV Surrogates Following Simulated Anal Intercourse to Aid Rectal Microbicide Development.
    J Acquir Immune Defic Syndr. 2024;96:18-22.
    PubMed     Abstract available


  382. REIS K, Wolf A, Perumal R, Seepamore B, et al
    Differentiated service delivery framework for people with multidrug-resistant tuberculosis and HIV co-infection.
    J Acquir Immune Defic Syndr. 2024;96:34-39.
    PubMed     Abstract available


    April 2024
  383. DORWARD J, Sookrajh Y, Lessells R, Bulo E, et al
    Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:e8-e11.
    PubMed    


  384. KABAMI J, Koss CA, Sunday H, Biira E, et al
    Randomized Trial of Dynamic Choice HIV Prevention at Antenatal and Postnatal Care Clinics in Rural Uganda and Kenya.
    J Acquir Immune Defic Syndr. 2024;95:447-455.
    PubMed     Abstract available


  385. YOUNGUI BT, Atwine D, Otai D, Vasiliu A, et al
    Integration of HIV Testing in a Community Intervention for Tuberculosis Screening Among Household Contacts of Patients with Tuberculosis in Cameroon and Uganda.
    J Acquir Immune Defic Syndr. 2024;95:431-438.
    PubMed     Abstract available


  386. SHADE SB, Gutin SA, Agnew E, Grignon JS, et al
    Cost Analysis of Short Messaging Service and Peer Navigator Interventions for Linking and Retaining Adults Recently Diagnosed With HIV in Care in South Africa.
    J Acquir Immune Defic Syndr. 2024;95:417-423.
    PubMed     Abstract available


  387. FU W, McClymont E, Av-Gay G, Dorling M, et al
    Retrospective Cohort Study on the Impact of the COVID-19 Pandemic on Pregnancy Outcomes for Women Living With HIV in British Columbia.
    J Acquir Immune Defic Syndr. 2024;95:411-416.
    PubMed     Abstract available


  388. MOAWAD MHED, Mohamed Shalaby MM, Hamouda E, Mahfouz A, et al
    Risk of Stroke Among HIV Patients: A Systematic Review and Meta-analysis of Global Studies and Associated Comorbidities.
    J Acquir Immune Defic Syndr. 2024;95:399-410.
    PubMed     Abstract available


  389. ERENRICH RK, Braun RA, Torres-Mendoza DM, Stevenson OL, et al
    Effectiveness of PrEPTECH: Findings From a 180-Day Randomized Controlled Trial of a Pre-Exposure Prophylaxis Telehealth Intervention.
    J Acquir Immune Defic Syndr. 2024;95:463-469.
    PubMed     Abstract available


  390. MUTETWA T, Liu Y, Silvera R, Evans M, et al
    Host Nuclear Genome Copy Number Variations Identify High-Risk Anal Precancers in People Living with HIV.
    J Acquir Immune Defic Syndr. 2024 Apr 15. doi: 10.1097/QAI.0000000000003409.
    PubMed     Abstract available


  391. ERLY S, Menza TW, Granillo L, Navejas M, et al
    Impact of COVID-19 on People Living with HIV: Data from Five Medical Monitoring Project Sites, 2020-2022.
    J Acquir Immune Defic Syndr. 2024 Apr 2. doi: 10.1097/QAI.0000000000003403.
    PubMed     Abstract available


  392. KENNEDY CE, Yeh PT, Verster A, Luhmann N, et al
    Do Peer Navigators Improve Initiation and Retention in HIV/VH/STI Treatment Programs for People From Key Populations? A Systematic Review of Effectiveness, Values and Preferences, and Cost.
    J Acquir Immune Defic Syndr. 2024;95:305-312.
    PubMed     Abstract available


  393. VOLK JE, Leyden WA, Lea AN, Lee C, et al
    Using Electronic Health Records to Improve HIV Preexposure Prophylaxis Care: A Randomized Trial.
    J Acquir Immune Defic Syndr. 2024;95:362-369.
    PubMed     Abstract available


  394. FRANCE AM, Panneer N, Farnham PG, Oster AM, et al
    Simulation of Full HIV Cluster Networks in a Nationally Representative Model Indicates Intervention Opportunities.
    J Acquir Immune Defic Syndr. 2024;95:355-361.
    PubMed     Abstract available


  395. LOGAN NZ, Kilmarx PH, Rolle I, Patel HK, et al
    Brief Report: Self-Reported HIV-Positive Status but Subsequent HIV-Negative Test Results in Population-Based HIV Impact Assessment Survey Participants-11 Sub-Saharan African Countries, 2015-2018.
    J Acquir Immune Defic Syndr. 2024;95:313-317.
    PubMed     Abstract available


    March 2024
  396. HICKEY MD, Grochowski J, Mayorga-Munoz F, Oskarsson J, et al
    Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People with HIV Who Are Virally Unsuppressed.
    J Acquir Immune Defic Syndr. 2024 Mar 27. doi: 10.1097/QAI.0000000000003421.
    PubMed     Abstract available


  397. LINNEMAYR S, Wagner Z, Saya UY, Stecher C, et al
    Behavioral economic incentives to support HIV care: Results from a randomized controlled trial in Uganda.
    J Acquir Immune Defic Syndr. 2024 Mar 27. doi: 10.1097/QAI.0000000000003420.
    PubMed     Abstract available


  398. QIAN Y, Zhang P, Wang L, Suo J, et al
    The association of intraocular efavirenz concentrations and HIV-1 viral load among persons with HIV.
    J Acquir Immune Defic Syndr. 2024 Mar 25. doi: 10.1097/QAI.0000000000003426.
    PubMed     Abstract available


  399. BUNTING SR, Feinstein BA, Vidyasagar N, Sheth NK, et al
    Psychiatry and Family Medicine Residents' Likelihood of Prescribing HIV Pre-Exposure Prophylaxis (PrEP) to Patients with Mental Illness and HIV Vulnerability.
    J Acquir Immune Defic Syndr. 2024 Mar 25. doi: 10.1097/QAI.0000000000003423.
    PubMed     Abstract available


  400. PATEL D, Williams WO, Wright C, Essuon A, et al
    CDC-Funded HIV Testing and Undiagnosed HIV Infection in Ending the HIV Epidemic in the U.S. Jurisdictions.
    J Acquir Immune Defic Syndr. 2024 Mar 23. doi: 10.1097/QAI.0000000000003424.
    PubMed     Abstract available


  401. WEISER J, Tie Y, Crim SM, Riedel DJ, et al
    Do HIV Care Outcomes Differ by Provider Type?
    J Acquir Immune Defic Syndr. 2024 Mar 7. doi: 10.1097/QAI.0000000000003410.
    PubMed     Abstract available


  402. MADLALA HP, Myer L, Geffen H, Rusch J, et al
    Inflammatory markers in pregnancy are associated with postpartum weight in South African women living with HIV on antiretroviral therapy.
    J Acquir Immune Defic Syndr. 2024 Mar 4. doi: 10.1097/QAI.0000000000003406.
    PubMed     Abstract available


  403. NUNEZ I, Ceballos-Liceaga SE, Torre A, Garcia-Rodriguez G, et al
    Clinical features and outcomes of mpox in people with and without HIV: a national comparative study.
    J Acquir Immune Defic Syndr. 2024 Mar 4. doi: 10.1097/QAI.0000000000003407.
    PubMed     Abstract available


  404. HANLEY S, Moodley D, Naidoo M, Brummel SS, et al
    THE IMPACT OF REGULAR SCREENING AND LIFESTYLE MODIFICATION ON CARDIOVASCULAR DISEASE RISK FACTORS IN SOUTH AFRICAN WOMEN LIVING WITH HIV.
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003387.
    PubMed     Abstract available


  405. OBOHO IK, Esber AL, Dear N, Paulin HN, et al
    Advanced HIV Disease in East Africa and Nigeria, in The African Cohort Study (AFRICOS).
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003392.
    PubMed     Abstract available


  406. BEN FARHAT J, TiendrebeogoMD T, Malateste K, Poda A, et al
    Effects of the Covid-19 pandemic on ART initiation and access to HIV viral load monitoring in adults living with HIV in West Africa: a regression discontinuity analysis.
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003404.
    PubMed     Abstract available


  407. TANAKA T, Oshima K, Kawano K, Tashiro M, et al
    Nationwide Longitudinal Annual Survey of HIV/AIDS Referral Hospitals in Japan From 1999-2021: Trend in Non-AIDS-Defining Cancers Among HIV-1-Infected Individuals.
    J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003389.
    PubMed     Abstract available


  408. CALZA L, Giglia M, Viale P
    Relationship Between Vitamin D Deficiency and Nonalcoholic Fatty Liver Disease in Patients With HIV-1 Infection.
    J Acquir Immune Defic Syndr. 2024;95:e5-e7.
    PubMed    


  409. MCCRARY AW, Hung F, Foster MC, Koech M, et al
    Letter to the Editor: Cardiac Dysfunction Among Youth With Perinatal HIV Acquisition and Exposure.
    J Acquir Immune Defic Syndr. 2024;95:e2-e4.
    PubMed    


  410. NABUKALU D, Yiannoutsos CT, Semeere A, Musick BS, et al
    Mortality Among HIV-Infected Adults on Antiretroviral Therapy in Southern Uganda.
    J Acquir Immune Defic Syndr. 2024;95:268-274.
    PubMed     Abstract available


  411. VAN HEERDEN JK, Meintjes G, Barr D, Zhao Y, et al
    Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:260-267.
    PubMed     Abstract available


  412. NGUMBAU NM, Neary J, Wagner AD, Abuna F, et al
    Cofactors of Partner HIV Self-testing and Oral PrEP Acceptance Among Pregnant Women at High Risk of HIV in Kenya.
    J Acquir Immune Defic Syndr. 2024;95:238-245.
    PubMed     Abstract available


    February 2024
  413. OPSTEEN S, Fram T, Files JK, Levitan EB, et al
    Impact of Chronic HIV Infection on Acute Immune Responses to SARS-CoV-2.
    J Acquir Immune Defic Syndr. 2024 Feb 8. doi: 10.1097/QAI.0000000000003399.
    PubMed     Abstract available


  414. DE WIT S, Bonnet F, Osiyemi O, Bisshop F, et al
    Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
    J Acquir Immune Defic Syndr. 2024 Feb 8. doi: 10.1097/QAI.0000000000003395.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.